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aa           Amino acids 
AP-1      Activator protein 1 
AP2      Activator protein 2 
Bcl2      B-cell lymphoma 2  
Bim      Bcl-2 interacting mediator 
BRCA-1     Breast cancer (type) 1 
CaMKIV     Ca2+/calmodulin-dependent protein kinase type IV 
CBP          CREB binding protein  
CD          Cluster of differentiation  
cDNA          Complementary DNA  
CHC          Chronic hepatitis C  
CLDN-1     Claudin 1 
CREB          cAMP response element binding protein  
dsRNA         Double stranded RNA  
EGF          Epidermal growth factor  
EGFR     Epidermal growth factor receptor 
eIF2α          Eukaryotic initiation factor 2 alpha  
EMSA          Electrophoretic mobility shift assay 
EphA2     Ephrin receptor A2  
ER          Endoplasmic reticulum 
ETS-1     E-twenty six-1 
FERM          Band 4.1, ezrin, radixin, moesin   
GAS          Gamma activated sequence  
GT          Genotype  
HA          Haemagglutinin  
HCC          Hepatocellular carcinoma  
HCV          Hepatitis C virus  
HCVcc         Cell-culture derived HCV  
HCVpp     HCV pseudo particle 
HEAT     Huntingtin, elongation factor 3 (EF3), protein 
phosphatase 2A (PP2A), and the yeast kinase TOR1 
HIV      Human Immunodeficiency Virus 
Huh7          Human hepatoma cell line 
I1PP2A     Inhibitor 1 of PP2A 
I2PP2A     Inhibitor 2 of PP2A  
IFN          Interferon 
IFN-α          Interferon alpha 
IGBP1     Immunoglobulin-binding protein 1 
IFN-ΑR         Interferon alpha/beta receptor 
IFN-γ     Interferon gamma  
IFNGR         Interferon gamma receptor  





IRES          Internal ribosomal entry site  
IRF          Interferon regulatory factor  
IRG         Interferon-regulated gene  
ISG          Interferon-stimulated gene  
ISG15      Interferon-sensitive gene 15 
ISGF3          Interferon-stimulated gene factor 3  
ISRE          Interferon-stimulated response element  
Jak             Janus kinase 
JFH                Japanese fulminant hepatitis  
JH          Jak homology 
JNK      c-Jun N-terminal kinases  
kDa          kilo Dalton 
LCMV     Lymphocytic Choriomeningitis  
LDL          Low density lipoprotein  
LDLR          LDL-receptor 
LPS      Lipopolysaccharide 
MAPK     Mitogen Activated Protein Kinase 
MAVS     Mitochondrial antiviral-signaling 
MCM5     Minichromosome maintenance complex component 5 
MEF      Mouse Embryonic Fibroblasts  
miRNA         Micro RNA 
MxA      Myxovirus A 
NCp       Nucleocapsid protein 
NCR      Non coding region 
NF-kB          Nuclear factor kappa B  
NK          Natural killer (cell)  
NS          Non-structural (protein)  
NIH3T3     Mouse embryonic fibroblast cell line 
NTPase         Nucleoside triphosphatase  
OA          Ocadaic acid  
OCLN     Occludin 
OAS          2’-5’ oligoadenylate synthetase  
ORF          Open reading frame 
PBMC     Peripheral blood mononuclear cells  
PCR          Polymerase chain reaction  
pDCs          plasmocytoid dendritic cells  
pegIFN-α        Pegylated interferon alpha  
PIAS          Protein inhibitors of activated STATs  
PKR          Protein kinase R  
PP      Protein Phosphatase 
PPM      Metal dependent Protein Phosphatase 
PPP      Phosphoprotein Phosphatase  
PP2A          Protein phosphatase 2A  





Prkaa1     Protein kinase, AMP-activated, alpha 1 catalytic subunit 
PRMT-1         Protein arginine methyltransferase  
PTPA          PTPase activator 
Pten      phosphatase and tensin homolog  
PTPase         Phosphotyrosyl phosphatase  
RdRp          RNA-dependent RNA-polymerase  
RIG-I          Retinoic-acid inducible gene-I  
RNAi          RNA interference  
SCID     Severe combined immunodeficiency 
SHP         SH2-containing phosphatase  
SH2          src homology 2  
SIE          Serum inducible element  
SOCS          Suppressor of cytokine signaling  
SP1      Specificity Protein-1 
SR-B1         Scavenger receptor class B type 1  
src          Rous sarcoma  
ssRNA                Single stranded RNA 
STAT            Signal transducer and activator of transcription 
STRN            Striatin, calmodulin binding protein 
SV40            Simian Vacuolating Virus 40  
TBK1          TANK-binding kinase 1  
TC-PTP         T cell protein tyrosine phosphatase  
TOR      Target of rapamycin 
Tyk2      Tyrosine kinase 2 
USP18 /UBP43      Ubiquitin-specific peptidase 18 
VISA     Virus-induced signaling adaptor 
VPR      Viral Protein R 
VSV      Vesicular stomatitis virus  












1.1 Protein Phosphatase 2A 
1.1.1 Structure and function of Protein Phosphatase 2A  	
  
Reversible posttranslational modifications are key mechanisms in regulating various 
cellular processes such as cell signaling, metabolism, and gene expression. One of the most 
important posttranslational modifications is the phosphorylation at serine, tyrosine, and 
threonine. The phosphorylated proteins are subjected to dephosphorylation by 
phosphatases. These phosphatases are classified into three groups based on their sequences, 
structures and catalytic mechanisms.  The first group contains phosphoprotein phosphatases 
(PPP) and metal (Mg2+ or Mn2+) dependent phosphatases (PPM). PP1, PP2A, PP2B, PP4, 
PP5, PP6 and PP7 belong to the PPP family and PP2C belongs to the PPM family. The 
second group is the superfamily of  the protein tyrosine phosphatases (PTPs) and the third 
group is the aspartate based phosphatases (Moorhead et al., 2007).   
	
  
The protein phosphatase 2A (PP2A) is one of the most widely expressed and extensively 
studied phosphatases. PP2A expression level represents up to 1.0 % of total cellular 
proteins and constitutes the major serine/threonine phosphatase in the cell (Virshup, 2000). 
PP2A is a multimeric holoenzyme composed by a scaffold A (65 kDa), a regulatory B, and 
a catalytic C (36 kDa) subunit (Janssens and Goris, 2001). Various isoforms of the 
regulatory B subunit are required for recognition and recruitment to specific substrates. The 





(Walter et al., 1989; Hemmings et al., 1990) subunits exist as two isoforms, α and β, 
encoded by distinct genes.  
	
  
PP2A-A protein was initially identified as a 61kDa protein, isolated from human 293 cells 
infected with polyoma virus overexpressing medium tumor antigen. This protein was 
partially digested with V8 protease and sequenced. Based on sequence information, 
oligonucleotide probes used for screening a cDNA library from human placenta. This novel 
protein was characterized as 61kDa protein having 15 HEAT repeats (Walter et al., 1989). 
Further, two isoforms α and β of the scaffold A subunit were cloned from porcine kidney 
and skeletal muscles and named PR65 (Hemmings et al., 1990). The PP2A-Aα and PP2A-
Aβ isoforms have 86% sequence homology (Hemmings et al., 1990). Their half life is 
approximately 10h (Zhou et al., 2003).	
  PP2A-Aα is expressed 10 fold more than PP2A-Aβ 
in H460 cells. 	
   PP2A-Aα and PP2A-Aβ have different affinities to protein-protein  
interactions. For example, PP2A-Aα and PP2A-Aβ both bind to polyoma virus middle 
tumour antigen whereas only PP2A-Aα binds to SV40 small t antigen (Zhou et al., 2003). 
	
  
The α and β isoforms of the catalytic subunit (PP2Acα and PP2Acβ) were cloned from 
different sources like bovine adrenal, porcine kidney, human liver, and plants (Green et al., 
1987; Stone et al., 1987; Arino et al., 1988; MacKintosh et al., 1990). Gene transcription 





and this may be the reason of almost 10 fold higher expression of PP2Acα than PP2Acβ at 
protein level (Khew-Goodall and Hemmings, 1988). 
Recently, a shorter spliced variant of the PP2Acα has been reported from fresh peripheral 
blood mononuclear cells (PBMC) (Migueleti et al., 2011). This newly identified variant, 
named PP2Acα2, lacks the 5th exon and is catalytically inactive (Migueleti et al., 2011). 
The regulatory B subunit has at least 18 different isoforms divided into B, B’, B’’ and B’’’ 











PP2A subunits coexist as dimeric (A-C) or trimeric (A-C-B) complex. The holoenzyme 
complex is required for the phosphatase activity on targets (Janssens and Goris, 2001). 
Although more than 150 targets are identified, the mechanisms by which B subunits 
mediated PP2A association to the target are not fully understood (Eichhorn et al., 2009). 
The association of PP2A holoenzyme has been described via the regulatory B subunits. 
However, several reports have showed that PP2A C and A subunits can also directly 
associate to proteins such as HIV1 NCp7:vpr, SV40 small t, Bcl2, or CaMKIV (Diagram 2) 
(Janssens and Goris, 2001). 
	
  






Generally, PP2A exerts its phosphatase activity through the association with the regulatory 
B subunits that determine the substrate specificity and the subcellular localization of the 
enzyme. However, the catalytic activity of PP2A can also be controlled by regulatory 
molecules such as α4 (see section regulation of catalytic activity of PP2A). The α4 (also 
termed as IGBP1) is the mammalian orthologue of yeast Tap42 protein which controls the 
TOR signaling (Onda et al., 1997). 
	
  
PP2A regulates many cellular functions including metabolism, DNA replication, 
transcription, RNA splicing, translation, cell cycle progression, cell senescence, apoptosis, 
cell transformation, morphogenesis, development, and neurotransmission (Cohen, 1989; 
Stemmer and Klee, 1991; Mumby and Walter, 1993; Hunter, 1995; Olsen et al., 2006; 
Moorhead et al., 2007). 
 
1.1.2 Regulation of PP2A-A, -B, and -C subunits expression 
Several transcription factors like AP1, AP-2α, ETS-1, SP-1, CREB regulate PP2A 
expression. The promoters of PP2Acα and PP2Acβ are GC rich and lack TATA and 
CCAAT boxes. PP2Acα promoter has a cAMP-regulatory element (CRE) and several SP-1 
binding sites (Khew-Goodall et al., 1991). Incubation of phosphorylated CREB with 
immunopurified PP2Ac results in a dephosphorylation on serine 133 and consequently the 
inhibition of the transcriptional activity of CREB (Wadzinski et al., 1993). Additionally, 





(Wadzinski et al., 1993). Further, it is reported that PP2Ac associates with autoactivation 
domain of calcium/calmodulin dependent kinase CaMKIVI and prevents phosphorylation 
of CREB (Anderson et al., 2004). We have reported that in hepatocytes HCV protein 
expression induces an ER stress response that leads to serine 133 phosphorylation on 
CREB and PP2Ac up-regulation (Christen et al., 2007). Moreover, down-regulation of 
CREB by siRNA did not up-regulate the PP2Ac expression by HCV proteins (Christen et 
al., 2007). Considering these observations, it is proposed that the expression of PP2Ac 
could form a feedback loop and inhibit the PP2A expression driven by CREB (Christen et 
al., 2007). Interestingly, Baharians and Schönthal have shown that PP2Ac protein level is 
maintained constant through an autoregulatory mechanism in mouse fibroblast cell line 
NIH3T3 that maintains to constant PP2Ac protein expression irrespective to regulation of 
transcription or RNA processing. Indeed, partial hepatectomy in mouse shows a constant 
protein expression level despite a 30 fold increase in PP2Ac mRNA (Kakinoki et al., 1992). 
Several reports have shown an increased PP2A mRNA expression during G1 phase in 
mammalian cells (Nakamura et al., 1992; Kikuchi et al., 1997). Consequently to this tight 
regulation of the protein expression level, it has been observed that PP2A level is constant 
in various mammalian cells and fission yeast through-out the cell cycle (Virshup et al., 
1989; Kinoshita et al., 1990; Ruediger et al., 1991). These data indicates that the 
accumulation of PP2Ac in the cell is not feasible because of the tight regulation and 
therefore raise the difficulties of PP2Ac expression experimentally. The half-life of the 
catalytic C subunit slightly varies from cell line to cell line. It has been reported that the 





Schönthal, 1998).  
 
The transcription of the PP2A-A subunit is regulated by AP-2α, ETS-1, CREB, and SP-1 
transcription factors (Chen et al., 2009). It has been demonstrated that the inhibition of 
PP2A catalytic activity by okadaic acid leads to an activation of JNK, and consequently 
enhanced c-Jun phosphorylation. Phosphorylated c-Jun forms a complex with c-Fos, AP-1 
and initiates PP2A-A transcription (Shanley et al., 2001). EGF exposure to rat fibroblasts 
208F cells activates AP-1 transcription factors leading to an increased transcription of 
PP2A-B subunit (Ozanne et al., 2000). These observations indicate an inter-regulatory 
effect of PP2A subunits i.e. an alteration of the activity and the expression level of one 
subunit can alter the expression of another one.  
 
Diagram 3: A simplified model showing regulation of gene transcription of PP2A subunits 






Another possibility of inter-regulation of PP2A subunits is through miRNA. Recent studies 
showed that miRNA-19 have multiple target genes as Bim (Bcl2L11), AMP-activated 
kinase (Prkaa1), phosphatases Pten and PP2A-B56ε (Mavrakis et al., 2010). Another report 
showed that the overexpression of miRNA-1 down-regulates PP2A-B56α leading to an 
enhanced Ca2+ release and an increased cardiac arrhythmogenesis (Terentyev et al., 2009). 
miRNA-34b is known to suppress the expression of α4 in transformed human embryonic 
kidney (HEKTER) and human lung cells. Chen et al., (Chen et al., 2011) have shown in 
HEKTER and human lung cells that down-regulation of miRNA-34b leads to an up-
regulation of α4 and consequently to a reduction of PP2A activity (Chen et al., 2011).  
 
1.1.3  Regulation of catalytic activity of PP2A 
1.1.3.1  Regulation of PP2A activity by posttranslational modifications on C-
terminal of the catalytic subunit 
 
The six amino acid (304TPDYFL309) residues on the C-terminus of the C subunit are 
conserved across species. The threonine 304, the tyrosine 307,  and the leucine 309 residues 
are known to undergo reversible posttranslational modifications. Phosphorylation at 
tyrosine 307 inhibits phosphatase activity (Chen et al., 1992). Recently, Wu et al. (Wu and 
Wilson, 2009) have reported that cotreatment of skeletal muscle microvascular endothelial 
cells with LPS and IFN-γ leads to nitration on tyrosine 307. This nitration increases the 
phosphatase activity by preventing tyrosine 307 from phosphorylation.  In line with these 





peroxynitrite donor substances increases nitration of tyrosine 307 and subsequently 
decreases phosphatase activity (Guner et al., 2009; Kohr et al., 2009). Similarly, casein 
kinase 2α has been shown to inhibit PP2A activity by phosphorylating the catalytic subunit 
at Y307 (Hériché et al., 1997). The catalytic activity of PP2A could be enhanced by 
treatment of cells with urate, a specific peroxynitrite scavenger, (Kohr et al., 2009). The 
phosphorylation on threonine 304 residues by auto-phosphorylation-activated protein 
kinases has been reported to inactivate the phosphatase activity (Guo and Damuni, 1993; 
Guo et al., 1993). An another posttranslational modification, the carboxymethylation on 
leucine 309 by methyltransferase (Favre et al., 1994; Floer and Stock, 1994; Xie and 
Clarke, 1994; Turowski et al., 1995) has been shown to enhance the interaction of the 
catalytic subunit to the PP2A-B55α subunit and activates the phosphatase activity (Bryant 
et al., 1999).  
 
1.1.3.2  Regulation of activity by varying holoenzyme complex 	
  
PP2A activity also depends on the interaction of the C subunit with B subunits or proteins 
other than PP2A components. For example, the interaction of the catalytic subunit with 
different isoforms of PP2A-B regulatory subunits forms different holoenzymes and delivers 
activity at different physiological level (Csortos et al., 1996; McCright et al., 1996). The 
complex mechanism behind substrates selection is still poorly understood. However, the 
selection and the association to the substrates are dependent on posttranslational 





PP2Ac subunit. Indeed, the carboxymethylation at leucine 309 on the C subunit is required 
for the association to the regulatory PP2A-B55α subunit (Bryant et al., 1999). Moreover 
the single mutation at tyrosine 307 or leucine 309 of  the C subunit forms mostly A-C 
dimer whereas the double mutations at tyrosine 307 and leucine 309  favours association to 
the α4 subunit instead of the A subunit (Chung et al., 1999). The regulation of PP2A 
activity by α4 is ambiguous. Several reports suggest that α4 inhibits PP2A activity while 
others showed an enhanced phosphatase activity. Indeed, Yoo et al. (Yoo et al., 2008) have 
reported that α4 forms a complex with PP2Ac in fetal as well as adult liver and inhibits the 
catalytic activity. In line with this observation other reports suggest an association of α4 
with PP2Ac and therefore an inhibition of the catalytic activity in HEK293 cells 
(Nanahoshi et al., 1998, 1999) and MEFs (Kong et al., 2009). In contrast, Nien et al., (Nien 
et al., 2007) have shown that the over-expression of mTOR together with α4 protein 
increases PP2A activity leading to increased STAT1α-PIAS1 binding.  Other reports 
confirm α4-mediated PP2A increased activity (Murata et al., 1997; Inui et al., 1998; Chung 
et al., 1999). Additional studies, using purified endogenously expressed protein inhibitors 
I1PP2A (Li et al., 1996a) and I2PP2A (Li et al., 1996b), have reported a direct association 
of the catalytic subunit to these inhibitors and consequently an inactivation of PP2A. An 
oncogenic transcription factor Hox11 has been shown to interact with PP2Ac and inhibits 
the phosphatase activity (Kawabe et al., 1997).  
 
Despite the constant protein expression level of PP2Ac, there are examples of altered 





have shown that simian virus 40 small t antigen (SV40ST) does not bind to either C subunit 
or A-B-C complex but rather binds to the A subunit of the A-C complex in the absence of 
B subunit and leads to decreased phosphatase activity. Therefore, the ectopic expression of 
SV40ST in the CV-1 cells leads to an increased phosphorylation of MAPK through 
inhibition of PP2A activity (Sontag et al., 1993). 
 
1.1.4 PP2A activity modulation by viruses and toxins  
PP2A subunits are the target of various molecules including drugs, viruses and toxins 
(Millward et al., 1999). For instance, protein kinase R (PKR) phosphorylates PP2A-B56α 
subunit at multiple serine and threonine residues. Phosphorylation of the PP2A-B56α 
subunit enhances PP2A phosphatase activity (Xu and Williams, 2000). Various viral 
particles associate to PP2A and modify its substrate specificity and activity. For instance, 
the SV40 small t antigen can associate to the C subunit and displaces the B subunits from 
A-C complex inhibiting the phosphatase activity (C. Kamibayashi, M. Mumby,  Adv. Prot. Phosphatases, 9 
(1995), pp. 195–210). Cayla et al. (Cayla et al., 2005) have shown that polyoma virus small t and 
middle T antigens bind to PP2A catalytic subunit and impart the tyrosine phosphatase 
activity in polyoma virus transformed cells. E4orf4, an adenovirus protein, associates to the 
PP2A-B55α and downregulates PP2A expression by modulating the transcriptional activity 
of AP-1 during late stages of viral infection (Kleinberger and Shenk, 1993). HIV proteins 
NCp7 and Vpr directly associate to the PP2A-B'δ subunit and initiate PP2A catalytic 






Various chemicals such as PP2A inhibitors are used in laboratories to study PP2A activity. 
Okadaic acid (from marine sponge) is one of the most widely used among them. The 
hydrophobic end of the okadaic acid binds to the hydrophobic cage within the binding 
pocket of PP2Acα (Xing et al., 2006). This hydrophobic cage is constituted by 4 amino 
acids (Q122, I123, H191, and W200).  Other chemicals like calcyculin A (also from marine 
sponge), tautomycin (an antibiotic from streptomyces spiroverticillatus), microcystin, 
nodularins (hepatotoxins from cynobacteria) cantharidin (from blister beetles) (Millward et 
al., 1999) are known as well to inhibit the activity of PP2A. 
  
1.1.5 Model for PP2A over-expression 
Various attempts have been made with only minor success to express PP2Ac. 
Microinjection of purified PP2Ac in fibroblast F9 cells potentiated the activity of promoters 
containing binding site for AP-1 leading to increased c-Jun expression and therefore an 
increased expression of PP2Ac (Alberts et al., 1993). However, this approach was 
successful but only in a small number of cells (Fernandez et al., 1990). In another approach, 
transient transfection of HA tagged PP2Ac at the N-terminus in NIH3T3 cells resulted in 
over-expression of PP2A and an increased phosphatase activity (Jaramillo-Babb et al., 
1996). Additionally, Ruediger and colleagues have generated an N-terminal PP2A-A 
mutant that binds specifically to C subunit, therefore, allowing the accumulation of core 
protein (A-C) in COS cells (Ruediger et al., 1997). Generation of a mouse model of PP2Ac 
over-expression is shown to be a challenging and frustrating task.  Indeed, PP2Acα gene 





normal and degenerated embryos from PP2Acα gene deleted mice express comparable 
level of total PP2Ac (PP2Acα and PP2Acβ) suggesting that the absence of PP2Acα cannot 
be compensated by PP2Acβ. Very recently, conditional null alleles of PP2Acα and 
PP2Acβ flanking loxP have been generated (Gu et al., 2012). PP2Acαfl/fl mice did not show 
any visible phenotype while Cre-mediated PP2Acα deleted homozygous mice die in the 
embryonic stage. PP2Acβ deleted homozygous mice did not show any physiological or 
morphological change.  
	
  
1.1.6 Clinical significance of PP2A 
Although, the expression of PP2A is tightly regulated (Baharians and Schönthal, 1998), the 
down-regulation of PP2Ac has been found during all-transretinoic acid induced 
differentiation of HL-60 cells (Nishikawa et al., 1994), during peroxisome proliferator-
activated receptor-γ induced adipocyte differentiation (Altiok et al., 1997) in hippocampus  
of patients  with Alzheimer's disease (Vogelsberg-Ragaglia et al., 2001). Over-expression 
of PP2Ac has been reported in response to colony-stimulating factor 1 in macrophages 








1.2 Interferon signaling 
1.2.1 The Interferon family 
Isaacs and Lindenmann discovered interferon five decades ago during their studies on viral 
interference (Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proceedings of the Royal Society of London. Series B, 
Containing papers of a Biological character 1957; 147 (927): 258–67). Interferons (IFNs) exercise their role in 
modulating antiviral and antiproliferative responses. They are grouped into three types: 
type I, type II and type III. Type I IFNs consists of IFNαs, IFNβ, IFNε, IFNκ, IFNω and 
IFNν (Heim, 2012). Presently, 13 different IFNαs have been reported in humans. All 
subtypes are encoded by distinct genes (Pestka et al., 2004). Interferon-γ is the sole member 
of type II IFNs. A recently discovered type III IFN is composed by IFN-λ2, IFN-λ3 and 
IFN-λ1, also known as IL28A, IL28B and IL29, respectively (Kotenko et al., 2002; 
Sheppard et al., 2002). 
 
Type I and type III IFNs are produced by human plasmacytoid dendritic cells (pDCs) and 
monocyte-derived dendritic cells (MDDCs) through a common mechanism involving RIG-
I, IPS1 (also termed as MAVS, VISA and Cardif), TBK1, IRF3 and NF-κB signaling 
molecules in response to viral infection (Siegal et al., 1999; Coccia et al., 2004; Österlund 
et al., 2007; Onoguchi et al., 2007). In response to antigens or mitogens type II IFNs are 







  Jak-STAT signaling pathway  
Type I IFNs exert their effect by binding to the interferon alpha/beta receptor (IFNΑR) that 
is composed of two subunits - IFNΑR1 (also known as alpha) and IFNΑR2 (known as 
beta). Type II IFNs (IFN-γ) binds to distinct receptor IFNGR consisting two subunits 
IFNGR1 and IFNGR2 (Aguet et al., 1988; Hemmi et al., 1994; Soh et al., 1994). Type III 
IFNs signal through the IFN-λ receptor comprising a unique IFN-λ chain and IL-10 receptor 
common with IL-10R2 chain. (Kotenko et al., 2002; Donnelly et al., 2004) (Diagram 4). 
 
 







Upon association of IFNs to their cognate receptors, the Jak kinases are phosphorylated and 
activated. Jaks (Janus Kinases) are cytoplasmic kinases. There are 4 known human Jaks, 
namely – Jak1-3 and Tyk2. Their molecular weight ranges from 120-140 kDa. Jaks are 
made up of 7-conserved JH (Jak Homology) domains characterized as JH1-JH7. JH1, 
located at the C-terminal end, is the kinase domain. JH2 is pseudokinase domain, 
responsible for recruiting substrates (Wang et al., 1995). The JH3-JH7 domains on N-
terminus recognize and bind to the receptor. JH3 and JH4 possess structural features of a 
potential SH2 (src homology 2)-like domain (Bernards, 1991). A fraction of JH4 and JH5-
JH7 region termed as FERM domain, bind to the cytoplasmic tail of transmembrane 
receptors (Hilkens et al., 2001) (Diagram 5).  
 
 
Diagram 5: Structure of Jaks. JH - Jak Homology, SH2 – src homology 2, FERM - 4.1, 
ezrin, radixin, moesin. 
 
STATs (signal transducers and activator of transcription) act as signal carrier as well as 
activator of transcription. In unstimulated cells, they predominantly localize in the 





transcription. There are 7 mammalian STATs known so far – STAT1-4, STAT5a, STAT5b, 
and STAT6. They are ubiquitously expressed except STAT4, which is mainly expressed in 
thymus and testes (Darnell et al., 1994; Heim, 1999).  
 
STATs have 6 domains. The transactivation domain at C-terminal end associates to the 
transcriptional co-activators CBP and p300 (Bhattacharya et al., 1996). The SH2 domain is 
involved in the recruitment of the STATs to activated receptors (Heim et al., 1995) and 
dimerization of activated STATs (Shuai et al., 1994). The DNA binding coiled-coil domain 
interacts with IRF9 and forms the ISGF3 complex. The N-terminus, containing a protein-
protein interaction domain, has been reported in regulation of STAT tyrosine 
dephosphorylation, CBP/p300 interaction, and nuclear transportation regulation (Zhang et 
al., 1996) (Diagram 6). 
 
 






1.2.3 Activation of the Jak-STAT signaling by IFN-α 
Cells exposed to IFN-α activate a cascade of events such as cross-linking of receptor chains 
(IFNΑR1 and IFNΑR2), activation of kinases (Jak1 and Tyk2), and phosphorylation of 
STAT1, STAT2 and STAT3 (Shuai et al., 1993; Heim et al., 1995). Activated STATs 
dissociate from receptor-kinase-substrate complex, form homo- or/and heterodimers, 
translocate to the nucleus, bind to promoter elements, and induce ISGs transcription 
(Horvath, 2000) (Diagram 7). This ISGs transcription includes an array of genes up-
regulation including antiviral genes (PKR, OAS1, MxA, ISG15), signaling genes (STAT1, 
STAT2, IRF9) and IFN-α itself (Lehtonen et al., 1997). 
 
STAT1 was first defined based on its role in mediating gene activation in response to 
interferon-γ (IFN-γ) (Darnell, 1997; Horvath and Darnell Jr, 1997). STAT1 contains a C-
terminal trans-activation domain, which possesses phosphorylation sites at tyrosine 701 and 
serine 727. Tyrosine phosphorylation of STAT1 on C-terminus is important for 
dimerization, DNA binding,  and transcriptional activation whereas serine phosphorylation 
leads to maximal transcriptional activity (Wen et al., 1995; Decker and Kovarik, 2000; 
Kovarik et al., 2001). STAT1 activity is also regulated through methylation on arginine 31 
residue by protein arginine methyl transferase 1 (PRMT1) (Mowen et al., 2001). Indeed, 
methylation of arginine 31 leads to a decrease STAT1-PIAS1 association, thereby, 







Recently, it has been reported that several ISGs can be induced by STAT1 in a tyrosine 701 
independent manner (Chatterjee-Kishore et al., 2000; Ramana et al., 2001). Indeed, tyrosine 
to a phenylalanine mutation of STAT1 does not alter the enhancement of the activity of Fas 
and FasL promoters. In contrast, a STAT1 serine 727 to an alanine mutation is less efficient 
than wild-type STAT1 in enhancing Fas and FasL promoters, as well as in inducing 
apoptotic cell death in cardiac myocytes (Stephanou et al., 2001). Moreover, 
phosphorylation on serine 727 has been shown to be critical for the C-terminal region of 
STAT1 to act as a transcriptional co-activator by binding to molecules such as MCM5 
(Zhang et al., 1998) and BRCA-1 (Ouchi et al., 2000).  
 
1.2.4 Negative regulation of the Jak-STAT pathway 
The constitutive activation of interferon signaling is harmful to the cell. Therefore, it is 
essential to regulate the interferon signal transduction cascade. As reported before, STATs 
are constitutively activated in many hematological malignancies (Gouilleux-Gruart et al., 
1996). The regulation of the Jak-STAT signaling is attributed to its various negative 
regulators at different levels. For instance, the inhibition of IFNs signaling by the 
Suppressors of Cytokine Signaling (SOCS) which constitutes the first level of inhibition at 
the receptor-kinase-STATs complex, occurs either by inhibiting Jaks activation or by 
preventing STATs binding to the receptor (Krebs and Hilton, 2001; Larsen and Röpke, 
2002). The SOCS family consists of 8 members SOCS1 – SOCS7 and CIS. SOCS1 and 





a complex fatal neonatal disease (Alexander et al., 1999) and die during neonatal period 
due to hepatotoxicity and multi-organ failure (Starr et al., 1998). SOCS1 deleted mice are 
resistant to viral infection due to an enhanced type I IFN signaling (Fenner et al., 2006). 







Diagram 7: IFN-α induced Jak-STAT signaling pathway. IFN-α binding to receptors 
causes their dimerization. Kinases (Jak1/Tyk2) are recruited to receptors and auto-
activated. Activated kinases phosphorylate STATs leading to their dimerization and ISGF3 
formation by association with IRF9, translocation to nucleus and activation of gene 
transcription.  
  
Downstream to the SOCSs inhibition, the protein inhibitor of activated STAT (PIAS) binds 
to hypomethylated STAT dimers and inhibits STAT-DNA interaction (Liu et al., 1998; 
Shuai, 2000; Mowen et al., 2001). PIAS1 and PIAS3 bind to STAT1 and STAT3, 
respectively. PIAS1 selectively inhibits interferon inducible gene and is essential for innate 
immunity. PIAS1 deleted mice show an enhanced protection against viruses and microbes 
(Liu et al., 2004).  
 
Another important negative regulator of the Jak-STAT pathway is the ubiquitin specific 
peptidase 18 (USP18/UBP43). Initially, USP18/UBP43 was considered as protease 
cleaving ubiquitin-like modifier ISG15 (Liu et al., 1999). USP18/UBP43 was recently 
found to exert a negative regulatory role independent to its ISG-deconjugating ability 
(Malakhov et al., 2002). USP18/UBP43 inhibits the activation of Jak1 by disrupting Jak1 
interaction with IFNΑR2 (Malakhova et al., 2006). USP18/UBP43 is induced by IFN-α 
(Der et al., 1998; Malakhova et al., 2002) and provides a negative feedback loop that 
restricts IFN-α signals. It has been reported that UBP43 deficient mice display a critical 





death (Ritchie et al., 2002; Malakhova et al., 2003). Interestingly, these animals are 
resistant to fatal cerebral infections caused by VSV and LCMV (Ritchie et al., 2004). We 
and others have shown that USP18/UBP43 is up-regulated in liver of CHC non-responders 
to pegIFN-α therapy (Chen et al., 2005a; Sarasin-Filipowicz et al., 2008) and contributes to 
the refractoriness to IFN-α stimulation in mouse liver (Sarasin-Filipowicz et al., 2009). 
Furthermore, USP18/UBP43 knockdown in cells enhances the antiviral activity of 
interferon against hepatitis C virus infection (Randall et al., 2006). 
 
STATs are dephosphorylated by a 45kDa isoform nuclear T-cell protein tyrosine 
phosphatase (TC-PTP), followed by nuclear export (ten Hoeve et al., 2002; Zhu et al., 
2002). It has been reported that SHP-2, a SH2 containing phosphatase, dephosphorylates at 
both tyrosine and serine residues on STAT5 and STAT1 in the nucleus (Wu et al., 2002; 
Chen et al., 2003). Recently, TC-PTP has been reported as a negative regulator of cytokine 
signaling. TC-PTP deleted mice display immune defects and developed systemic 
inflammatory diseases like sialadenitis, gastritis, chronic myocarditis and nephritis.  These 
animals have an elevated serum of IFN-γ causing death of animals within five weeks. 
(Heinonen et al., 2004) (Diagram 8). Additionally, we have demonstrated that PP2A 
inhibits the Jak-STAT pathway at the level of STAT-DNA interaction by altering the 






Diagram 8: Negative regulation of IFN-α induced Jak-STAT signaling pathway. Jak-
STAT pathway is negatively regulated in cytoplasm (by USP18, SOCSs, 






1.2.5 Refractoriness of the IFN signaling 
It is well known that the IFNs induction becomes rapidly refractory. Indeed, maximal 
induction of the IFN signaling pathways occurs within the initial 2 hours of IFN stimulation 
and continuous exposure to IFNs leads to a “desensitization” and consequently to an 
absence of response to further stimulation for the next 2-3 days (Larner et al., 1986). 
Refractoriness has been also reported in the liver of mice injected with mouse IFN-α 
(Sarasin-Filipowicz et al., 2009). In vivo, subcutaneous injection of IFN-α make 
hepatocytes refractory within hours after the first injection and remain so for at least 2 days.  
 
Studies on negative regulator of IFN-α have revealed SOCSs as early inhibitors of STAT 
phosphorylation within 2-4 hours of IFN-α stimulation - whereas USP18/UBP43 is 
involved in long lasting refractoriness. Interestingly, IFN-β induced signaling in mice liver 
and IFN-γ induced signaling in intestine are not subjected to refractoriness (Makowska et 
al., 2011).  
 
1.2.6 IFN-α induced antiviral activity 
The Jak-STAT signaling cascade plays a major antiviral role by inducing the ISGs such as 
double-stranded RNA (dsRNA) activated protein kinase R (PKR), 2'-5' oligoadenylate 





triggers the phosphorylation of PKR resulting in the phosphorylation of the α subunit of 
eukaryotic initiation factor (eIF2α). The phosphorylation of eIF2α leads to the inhibition of 
translation of both viral and cellular proteins, providing the antiviral and antiproliferative 
effect of IFNs (Sadler and Williams, 2008). OAS-dependent activated RNase L catalyses 
the cleavage of viral and cellular single-stranded RNAs (ssRNAs) (Carroll et al., 1996). 
RNase L plays an important role in positive feedback mechanisms and enhancement of the 
innate immunity in the cells. Presence of small RNA in the virally infected cells induces the 
antiviral innate immunity. Indeed, small self-RNA generated by RNase L amplifies the 
antiviral innate immunity by producing antiviral cytokines like IFN-β (Malathi et al., 
2007). Marschall and colleagues have reported that the multiplication of negative-stranded 
RNA viruses such as influenza C viruses was suppressed in cells expressing Mx proteins, 
an IFN-α inducible GTPases (Marschall et al., 2000).  
 
1.2.7 Clinical significance of alteration of the Jak-STAT signaling  
Defect of Jak-STAT1 signaling is beneficial for HCV to escape from the host antiviral 
activity and to establish persistent infection. HCV infection results in an inhibition of the 
IFN-induced antiviral effector system through the phosphorylation of PKR and eIF2α, and 
a decrease of IFN-α receptor expression in the liver through disruption of the IFN-α 
signaling (Yatsuhashi et al., 1999). The expression of the entire HCV ORF in cell lines 
inhibits the formation of ISGF3 and its subsequent DNA binding (Heim et al., 1999). Lack 
of functional Tyk2 in melanoma cell reduces tyrosine phosphorylation of STAT1 and 





any developmental defects but have compromised innate immunity to viral disease (Durbin 
et al., 1996). Impaired Jak-STAT signaling due to mutation in IL-2 receptor and Jak3 has 
been reported in human X-Linked Severe Combined Immunodeficiency  (SCID) (Puck et 
al., 1997) syndrome.  Moreover, a V617F mutation has been reported in the coding 
sequence of Jak2 in human myeloproliferative disorders, which leads a gain of function 
causing expansion of the myeloproliferative disorder (Kralovics et al., 2005).  
 
1.2.8 PP2A and the Jak-STAT signaling  
We have reported previously that the expression of HCV proteins in osteosarcoma cell lines 
or in transgenic mice liver leads to an up-regulation of PP2A catalytic subunit and inhibits 
the IFN-α signaling at the STAT-DNA interactions level (Heim et al., 1999; Blindenbacher 
et al., 2003). We have consistently observed an up-regulation of PP2Ac in human cell lines 
that inducibly express HCV proteins, HCV transgenic mice, and human liver biopsy from 
chronic hepatitis C (CHC) patients (Duong et al., 2004). The over-expression of PP2Acα in 
Huh7 cells results in a reduction of PRMT1 activity, a hypomethylation of STAT1, an 
increased STAT1-PIAS1 association, and consequently, an inhibition of STAT1-DNA 
binding (Duong et al., 2006). The PP2A-induced inactivation of PRMT1 can be reversed in 
vitro by treatment with a methyl-group donor S-adenosyl-L-methionine (SAMe) (Duong et 
al., 2006). It is reported that treatment of cellular extracts from U973 cells stimulated with 
IFN-γ with purified PP2Ac resulted in a decreased GAF-DNA binding (Eilers et al., 1995). 
Further, Fielhabler and colleagues (Fielhaber et al., 2009) have shown that PP2A forms a 





increases the activated STAT1 content into the nucleus and up-regulates of Jak-STAT 
signaling in response to IFN-γ. Additionally, it is shown that inhibition of PP2A in human 
CD4+ T or T lymphoma or Jurkat T cells increases the serine phosphorylation on STAT6 
and STAT3 (Woetmann et al., 1999, 2003). 
 
1.3 The Hepatitis C virus 
1.3.1 Structure of HCV 	
  
Hepatitis C virus is a member of Hepacivirus genus of the Flaviviridae family.  
(Moradpour et al., 2007). HCV is small (55–65 nm in size) (Shimizu et al., 1996), 
enveloped, positive-sense single-stranded RNA virus. HCV was identified as a causative 
agent of a liver disease and CHC. It was previously defined as a non-A, non-B hepatitis 
(Choo et al., 1989). CHC can lead to liver cirrhosis and hepatocellular carcinoma. Six 
distinct genotypes (GT) of HCV with 65-70 % sequence homology have been reported so 
far (Simmonds et al., 2005).   
 
The HCV genome is approximately 9.6kb long and is composed of a 5’-non-coding region 
(NCR), an open reading frame (ORF) for polyprotein and a 3’-NCR. The HCV ORF 
encodes approximately 3000 amino acids (aa) (Suzuki et al., 1999) long precursor 
polyprotein which is processed into at least ten proteins by viral and cellular proteases. 
These proteins are grouped into structural (core, E1 and E2) and non-structural (p7, NS2, 





whereas E1 and E2 are embedded into lipid and are responsible for recognition of receptor 
and entry of the virus into the host cell (Grakoui et al., 1993b). The p7 is an ion channel 
protein. It has been shown using an expression plasmid encoded for NS2 and NS3 that the 
major part of NS2 and the N-terminal part of NS3 constitutes a zinc-dependent 
metalloproteinase and cleaves the NS2/NS3 junction. The cleavage of the remaining non-
structural polyprotein to generate individual protein is performed by NS3-4A protease. 
(Grakoui et al., 1993a; Hijikata et al., 1993). NS3 contains a serine protease and a 
NTPase/RNA helicase activity. The NS4A is a cofactor for NS3 proteases. It is shown that 
the processing of the polyprotein occurs at ER membranous web which is formed by NS4B 
(Egger et al., 2002; Gosert et al., 2003). The function of NS5A is not clear though it has 
been proposed that NS5A (hyper)phosphorylation plays an important role in the regulation 
of NS5A interaction to the host protein (hVAP-A) as well as to viral proteins (NS3, NS4B). 
The hyperphosphorylation of NS5A disrupts the interaction with hVAP-A leading to a 
decrease viral replication (Evans et al., 2004) In line with this observation, substitution of 
serine by alanine residue within the central cluster 1 led to a reduction of phosphorylation 
and an enhance RNA replication (Appel et al., 2005). Furthermore, NS5A interacts with 
IFN-α inducible host protein PKR and inhibits its activity leading to a decrease of IFN-α 
mediated antiviral activity (Gale et al., 1998). NS5B contains an RNA-dependent-RNA-
polymerase activity (RdRp) and is essential for HCV replication (Behrens et al., 1996; Ishii 






The highly conserved NCRs are required for viral replication. The 5’-NCR contains an 
internal ribosomal entry site (IRES) that is responsible for the initiation of a cap 
independent translation of viral protein.  Recently, it has been reported that the liver 
specific miRNA-122 associates to the 5’-NCR of HCV RNA and positively modulates 
HCV replication (Jopling et al., 2005). The 3’-NCR consists of three regions. A poorly 
conserved 40 bases among various genotypes, a variable length poly(U)/poly-pyrimidine 
tract, and an element of highly conserved 98 bases (Tanaka et al., 1995, 1996; Yamada et 
al., 1996; Kolykhalov et al., 2000). Similarly to the 5’-NCR, the 3’-NCR is required for 
HCV replication (Diagram 9). 
 








1.3.2 Pathogenesis  	
  
The primary target cell for HCV infection is the hepatocyte, and potentially additional 
targets are B-lymphocytes and dendritic cells Since the discovery of HCV in 1989 (Choo et 
al., 1989) much has been learned about HCV replication.  Most of the knowledge obtained 
on HCV replication are based on genomic and subgenomic replicon systems 
(Bartenschlager, 2002). So far, only humans are known as host as well as reservoir of HCV 
(Chisari, 2005). Indeed, chimpanzees have been infected experimentally but no HCV 
transmission from one chimpanzee to another has been reported. Efforts are being made to 
generate humanized mouse models, but until now only chimpanzees exist as immuno-
competent animal model.  
 
Viral entry is the first step of replication and needs cooperative interaction between several 
viral and host factors. HCV entry is internalized in a clathrin-dependent endocytosis that 
requires various host factors engaging viral E2 protein and channelizing the process. 
Several reports have shown that HCV is internalized through various host factors. Indeed, 
the HCV virus envelope protein E2 interacts with tetraspanin CD81, expressed on various 
cells including hepatocytes and B lymphocytes, and together with cellular factors induces 
HCV internalization (Pileri et al., 1998; Cormier et al., 2004; Molina et al., 2008). HCV is 
inable to interact with cells when human low-density lipid receptor (LDLR) is expressed at 
normal level. The ectopic expression of LDLR in Cos7 cells enables the HCV to bind and 





HCV entry in primary human hepatocytes has shown that the down-regulation of LDLR by 
25-hydroxycholesterol or the up-regulation of LDLR by squalestatin leads to a decrease or 
to an increase viral RNA, respectively (Molina et al., 2007). A recent report suggests that 
the LDLR is not essential for HCV entry, but the physiological function of LDLR is 
important for optimal replication of the HCV genome (Albecka et al., 2012). 
 
HCV can also associate to an another receptor termed as scavenger receptor class B type I 
(SR-BI), which then initiates the internalization (Scarselli et al., 2002), The SR-BI-based 
viral entry is mediated by Apo-B containing lipoprotein in which HCV E2 protein first 
interacts with Apo-B containing lipoprotein and then this complex interacts with SR-BI 
receptor (Maillard et al., 2006). A tight junction component, claudin-1 (CLDN1) was found 
to be a co-receptor for the HCV entry. Unlike CD81 and SR-BI that are required at the 
initial stage of HCV attachment to the receptors, CLDN1 is required at late stage of viral 
entry (Evans et al., 2007). Recently another tight junction protein, occludin (OCLN) has 
been found as an entry factor. Indeed, silencing of OCLN led to a decrease HCVpp 
infection in Hep3B cells as well as a decrease HCVpp and HCVcc infection in Huh7.5 
cells. And, inversely, the over-expression of OCLN in NIH-3T3 cells enhances the HCVpp 
infection by approximately 120 fold (Ploss et al., 2009). Eventually, the ephrin receptor A2 
(EphA2) and epidermal growth factor receptor (EGFR) have been identified as viral entry 
host factors (Lupberger et al., 2011). It has been hypothesized that EGFR activation helps 
in HCV binding to cells by modulating intracellular or cell surface trafficking of CLDN1, 





2. Aims of the PhD thesis project 
The hepatitis C virus is a major pathogen that causes liver cirrhosis and hepatocellular 
carcinoma. Current standard IFN-α based therapies are costly and elicit severe side effects. 
Moreover, existing IFN-α based therapies are not effective in all HCV infected individuals. 
We have previously reported that HCV infected patients who had a constitutive up-
regulation of ISGs do not respond to IFN-α based therapies (Sarasin-Filipowicz et al., 
2008). We have also reported that HCV infection induces PP2Acα over-expression in 
human individuals (Duong et al., 2004) which encourages us to study further.  
The aims of this PhD thesis are: 
 
2.1 Analysis of the molecular mechanism used by PP2Ac to inhibit IFN-α induced 
antiviral activity. 
2.2 Assessment of the role of PP2Ac over-expression on HCV replication 














3. Materials and methods  	
  
Materials and methods for the aims (section 2.1 and 2.2) - ‘‘Analysis of the molecular 
mechanism used by PP2Ac to inhibit IFN-α induced antiviral activity’’ and ‘‘Assessment of 




Materials and methods for the aim (section 2.3) ‘‘Identification of B subunits that modulate 
the dual effect of PP2Ac’’ is described in further sections 3.1 and 3.2. 
 
3.1 Silencing of PP2A-A and -B subunits  
 
The sh-RNA sequence for various subunits were designed using online software 
from Promega. The short-hairpin oligos targeting PP2A-A, -B subunits and 
scrambled oligos were cloned into psiSTRIKE-Puromycin vector (Promega) that 
allows contitutive expression of inserts. Plasmids encoding sh-RNA against various 
B and A subunits were transfected into Huh7 cells and clones were selected into 
puromycin containing medium. Details of sh-RNA oligos for silencing of PP2A-A 
and -B subunits are listed below. 
Sh-RNA oligos 












































































Table 1: List of forward and reverse primers used. All primers used were designed across 








Genes Fwd (5`-3`) Rev  (5`-3`)
1 PPP2R1A (PP2A-Aa) CTGGACAACGTCAAGAGTGAGATC CCGAGTCCTGCTCGTCAGA
2 PPP2R2A (PP2A-B55!) TCAGTGGTGTTTTTCTCAGGTGAA GACAACTCTACCACCTTTATCTCCTGTT
3 PPP2R5A (PP2A-B56!) AACACTGGAATCCGACCATTG AAAGCTTGCCATTCATTTCCAT
4 PPP2R5B (PP2A-B56") CACCTGCAGCTGGTATATGAGTTT CACGGAGGGCTGGAAGTCT
5 PPP2R2B (PP2A-B55") CCCGCAAAATCAACAACAGTT TAATGTCAGCTTCGGTCGCATA
6 PPP2R2C (PP2A-B55#) CGGGAACCAGAGAGTAAAAATGC TGGAAAGTGCTGTACACGTCGTA
7 PPP2R2D (PP2A-B55$) TTCGGATAGCGCCATCATG CGTGTCTCTATCAAACATCCTGAAG
8 PPP2R5C (PP2A-B56#) CAAAGCCAATCCCCAGTACAC CCATTGCAACCGGAATGC
9 PPP2R5D (PP2A-B56$) CCATCATGTTCCCTGCACTCTA GTCCATGGATTGTCTTGTTCCA
10 PPP2R5E (PP2A-B56%) GATCCTTCACTCACAGAACCAGTTATT CCCAAGGAACATGACCTCTTTT
11 PPP2R3A (PP2A-B72!) GCCCAACTGCAGCTCTCTAGA GGGTATCCACCACATCCTGAA
12 PPP2R3B (PP2A-B72") GACTGCCTCTGCCAGATGCT GCAGCGTGATCTTCCCTTCA
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SUMMARY. Mammalian cells have developed several mech-
anisms to sense viruses and initiate adequate responses
such as production of interferons. Interferons activate the
antiviral response through the Jak-STAT signalling path-
way. To establish a chronic infection, viruses need to coun-
teract this barrier of defence. The hepatitis C and hepatitis
B viruses are known to up-regulate the expression of pro-
tein phosphatase 2A (PP2A). In this study, we show that
PP2Ac associates with Jak1/Tyk2/STAT1 and reduces
Jak1/Tyk2/STAT1 phosphorylation resulting in an impair-
ment of the IFNa-induced HCV antiviral response. Using
the fully infectious HCV cell culture system (HCVcc), we
demonstrate that the PP2A catalytic activity is not
required to block the antiviral effect of IFNa, although it is
needed to support HCVcc replication. Our data suggest an
important contribution of virus-induced PP2Ac up-regula-
tion in the establishment of a chronic infection.
Keywords: antiviral activity, HCV replication, interferon a,
protein phosphatase 2A, STAT1.
INTRODUCTION
The innate immune system is the first response of the
host against invasion by pathogens. Cells of the immune
system have developed detection methods to sense viruses
and activate the production of interferons (IFNs) [1,2].
IFNs associate with their cognate receptors and initiate
the Jak-STAT signalling pathway. The binding of IFNs to
the receptor leads to receptor dimerization and activation
of the Janus kinases (Jaks) [3]. Signal transducer and
activator of transcription (STATs) are then recruited and
phosphorylated by the Jaks. Activated STATs regulate
transcription by association with the promoters of IFN-
stimulated genes (ISGs) [4,5]. IFNa activates important
antiviral effector systems such as double-stranded RNA
(dsRNA), activated protein kinase R (PKR), 2′-5′ oligoade-
nylate synthetase (OAS) and Mx proteins [6–8]. The regu-
lation of the Jak-STAT pathway occurs at various levels
and is crucial to switch off the interferon signal. Several
inhibitors are involved such as suppressor of cytokine sig-
nalling (SOCS) [9], protein inhibitor of activated STAT
(PIAS) [10], T-cell protein tyrosine phosphatases (TC-PTP-
ases) [11], and ubiquitin-specific peptidase 18 (USP18)
[12].
The major serine/threonine phosphatase, protein phos-
phatase 2A (PP2A) is ubiquitously expressed in all cell
types. PP2A is a trimeric enzyme composed of a scaffolding
subunit A, a regulatory subunit B and a catalytic C sub-
unit [13]. The C subunit associates with the A subunit to
form the catalytic core [14]. Heretofore attempts to over-
express the fully active PP2A catalytic subunit (PP2Ac)
failed because of the autoregulatory mechanism that main-
tains PP2A expression level constant [15]. However, addi-
tion of a peptide sequence derived from the influenza
haemagglutinin protein (HA) at the N-terminal end of the
PP2Ac sequence has been reported to increase the phos-
phatase activity [16] and resulting in an impairment of the
enzymatic activity of the protein arginine methyl transfer-
ase 1 (PRMT1) [17,18]. This autoregulatory mechanism is
disrupted in chronic hepatitis C (CHC) and chronic hepati-
tis B (CHB) viral infection leading to an over-expression of
the catalytic subunit [19,20]. The regulatory B subunit
recognizes a similar sequence of the A subunit and deter-
mines the subcellular localization of the heterotrimeric
enzyme as well as the substrate specificity [21]. The activ-
ity of PP2A is regulated by post-translational modifications
on the C subunit. Indeed, the phosphorylation on tyrosine
307 inhibits PP2A activity [22], and the carboxymethyla-
tion on leucine 309 controls the interaction of the catalytic
Abbreviations: CHC, chronic hepatitis C; ISGs, IFN-stimulated
genes; OAS, oligoadenylate synthetase; PKR, protein kinase R.
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subunit with the Ba subunit [23]. Previously, we have
reported that PP2Ac over-expression impairs the IFNa
signalling at the STAT1-DNA-binding level by a direct
association of PP2Ac with PRMT1 leading to the inhibition
of PRMT1-induced STAT1 methylation [18].
We show here that PP2Ac associates with Jak1/Tyk2/
STAT1 upon IFNa stimulation and blocks Jaks/STAT1
phosphorylation. Interestingly, this inhibitory effect is inde-
pendent of the catalytic activity and is abolished by high
concentrations of IFNa. Using a functional assay based on
the HCV fully infectious system, we demonstrate that the
over-expression of a PP2Ac mutant lacking the catalytic
activity is sufficient to impair the antiviral activity of IFNa.
Our data reveal a dual role for PP2Ac; first to support HCV
replication and second to impair the IFNa-mediated
antiviral activity favouring the establishment of a chronic
infection.
EXPERIMENTAL PROCEDURES
Reagents, antibodies and plasmids
Human IFNa and the protease inhibitor cocktail were
obtained from Roche (Hoffmann La Roche, Basel, Switzer-
land). Mouse IFNa was a generous gift from Prof. Radek
Skoda. Lipofectamine 2000 was from Invitrogen (LuBio-
Science GmbH, Buchs, Switzerland). Protein A-Sepharose
4B beads, okadaic acid and Actin antibody were from
Sigma-Aldrich (Fluka Chemie GmbH, Lucerne, Switzer-
land). PP2Ac and pY1022/23-Jak1 antibodies were from
Millipore (Millipore AG, Zug, Switzerland). HCV NS3A and
Tyk2 antibodies were from Abcam (Cambridge, UK). HCV
core antibody was from Thermo Scientific (Perbio Science,
Lausanne, Switzerland). STAT1 antibody was from Santa-
Cruz Biotechnologie (LabForce AG, Nunningen, Switzer-
land). pS473-Akt, Akt, pS727-STAT1, pY1054/55-Tyk2,
pY701-STAT1 and PRMT1 antibodies were from Cell Sig-
nalling (BioConcept, Allschwil, Switzerland). H4 and
MetR3H4 antibodies were purchased from Abcam. HRP-
conjugated secondary antibody (NA931V) for HCV detec-
tion was from GE Healthcare (GE Healthcare Europe
GmbH, Glattbrugg, Switzerland).
Wild type (pDE3-HA-Ca-WT) and mutated PP2Aca plas-
mids (pDE3-HA-Ca-D88N and pDE3-HA-Ca-H118N) tagged
with single HA coding sequence immediately downstream
to the human PP2Aca initiation codon were a gift from
Dr. Brian Hemmings. pSIH1-puro-shPP2Ac and pSIH1-
puro-shPRMT1 were generated by digestion of the pSIH1-
puro-STAT3 shRNA plasmid (Addgene, no. 26596) and
insertion of short-hairpin RNA sequence against PP2Aca
or PRMT1, respectively. The control plasmid was pur-
chased from Addgene (no. 26597). Lentiviral packaging
plasmids were a gift from Prof. Martin Stern. Plasmid Luc-
JC1 containing codons 1-846 of J6/CF and 847-3033 of
JFH1 was kindly provided by Prof. Ralf Bartenschlager.
Mice
Eight weeks old male C57BL/6 mice were used for the
experiment. The animals were bred and maintained in the
University Hospital Basel animal facility. They were injected
(n = 2) subcutaneously with 1000 IU/mL mIFNa or PBS
for 1 h and the liver was collected. All animal experiments
were conducted with the approval of the animal care com-
mittee of the canton Basel-Stadt (Switzerland).
Cell lines
Huh7, Huh7.5.1, UPP2A-C8 and stable silencing PP2Aca
cell lines are described elsewhere [17].
SDS-PAGE, immunoblotting and immunoprecipitation
Cells were lysed in whole-cell lysis buffer containing 50 mM
Tris HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.1% Triton
X-100, 10 mM PMSF and 1 mM orthovanadate. Lysates were
cleared by centrifugation and quantified by Bradford (Bio-
Rad Protein Assay, Bio-Rad Laboratories AG, Reinach, Swit-
zerland). Proteins were resolved by SDS-PAGE, transferred
onto nitrocellulose membrane and probed with specific anti-
bodies. Immunoprecipitation was performed as described pre-
viously [18]. Densitometry analysis of protein bands was
performed using the public domain NIH Image program
(developed at the U.S. National Institutes of Health and avail-
able on the Internet at http://rsb.info.nih.gov/nih-image/).
Electrophoretic mobility shift assay
Nuclear extracts and mobility shift assay (EMSA) were per-
formed as described previously [18].
Lentiviral particle production and transduction
pSIH1-puro-control shRNA, pSIH1-puro-shPP2Ac and
pSIH1-puro-shPRMT1 were cotransfected with packaging
vectors into HEK293T cells using Lipofectamine 2000
according to the manufacturer’s instructions. Supernatants
containing lentiviral particles were cleared by centrifuga-
tion and stored at !70 °C.
Huh7.5.1 cells were transduced with 1MOI of lentiviral
particles for 3 days, and PP2Ac or PRMT1 expression was
analysed by immunoblotting and quantitative PCR.
PP2Ac primers were 5′-CCACAGCAAGTCACACATTG
G-3′ and 5′-CAGAGCACTTGATCGCCTACAA-3′. PRMT1
primers were 5′-GACATCCAAAGATTACTACTTTGACTC
CTA-3′ and 5′-GCGCACCTCGTCCTTCAG-3′.
Hepatitis C virus particle production in cell culture
(HCVcc) and infection of Huh7.5.1 cells
RNA preparation and electroporation were performed as
described [24]. Huh7.5.1 cells were infected with 1MOI of
© 2013 John Wiley & Sons Ltd





HCVcc strain JC1 particles for 3 days, and replication was
analysed by immunoblotting, qPCR and immunostaining
[24]. HCV primers were 5′-AGGAGGCCCGCACTGCCATA-3′
and 5′-CTGGCGCGGCAACGTCTGTA-3′.
Analysis of interferon-stimulated gene expression
Total RNA extraction, cDNA synthesis and SYBR-based
quantitative PCR were performed as described elsewhere
[17]. Primers were designed across exon–exon sequences
to avoid genomic DNA amplification. STAT1 primers were
5′-TCCCCAGGCCCTTGTTG-3′ and 5′-CAAGCTGCTGAAGT
TCGTACC-3′. IP10 primers were 5′-CGATTCTGATTTGC
TGCCTTATC-3′ and 5′-GCAGGTACAGCGTACGGTTCT-3′.
GBP1 primers were 5′- TGAACAAGCTGGCTGGAAAGA-3′
and 5′-ACATCCAGATTCCTTTAGTGTGAGACT-3′. SOCS1
primers were 5′- CCCCTTCTGTAGGATGGTAGCA-3′ and
5′-TGCTGTGGAGACTGCATTGTC-3′. GAPDH primers were
5′- GCTCCTCCTGTTCGACAGTCA-3′ and 5′- ACCTTCCCCA
TGGTGTCTGA-3′.
Cell proliferation assays
Viable cell quantification was performed using CellTiter 96
Aqueous One Solution Cell Proliferation Assay (Promega
AG, D€udendorf, Switzerland), according to the manufac-
turer’s instructions.
Statistical analysis
Statistical analysis was performed using Prism software
(GraphPad Software, Inc., La Jolla, CA, USA). Continuous
data are expressed as the mean ! standard error of the mean
(SEM) and were analysed using a Fisher’s t-test. A two-tailed
P value < 0.05 was considered statistically significant.
RESULTS
Alteration of PP2Ac expression modulates STAT1
tyrosine phosphorylation
We have previously reported that PP2Ac is up-regulated in
patients with CHC and impairs IFNa-mediated Jak-STAT
signalling through the alteration of PRMT1-induced
STAT1 arginine methylation [18]. We now show that in
the mouse liver, PP2Ac is bound to STAT1 upon IFNa
stimulation suggesting a potential role of PP2A in the
direct regulation of STAT1 activation (Fig. 1a). PP2A is a
major serine/threonine phosphatase, however, its auto-
dephosphorylation capacity on tyrosine residues suggests
that it could be a tyrosine phosphatase under particular
conditions [25]. We therefore investigated the effect of
PP2Ac over-expression on STAT1 phosphorylation using
UPP2A-C8 cells that allow the inducible over-expression of
PP2Ac (Fig. 1b). We first performed a dose-response
experiment. Control (Tet+) and PP2Ac over-expressing
(Tet-) cells were exposed to increasing doses of IFNa and
pY-STAT1 signal was analysed by immunoblotting. Fig-
ure 1c shows enhanced STAT1 phosphorylation that
reached the maximal level with 500 IU/mL of IFNa in con-
trol and PP2Ac over-expressing cells (lanes 5 vs 11 and 6
vs 12). We did not observe any difference of the pY-STAT1
signal between control and PP2Ac over-expressing cells at
500 and 1000 IU/mL IFNa. However, we noticed a reduc-
tion in pY-STAT1 signal in PP2Ac over-expressing cells
treated with 50 and 100 IU/mL IFNa compared with con-
trol cells (Fig. 1c; lanes 3 vs 9 and 4 vs 10). Thus, to
investigate further the effect of PP2Ac on STAT1 phos-
phorylation, we decided to perform further experiments
using 100 UI/mL of IFNa.
Next, we studied the effect of PP2Ac over-expression on
IFNa-induced STAT1 and IP10 expression. Our results
show a significant diminution of STAT1 and IP10 expres-
sion in PP2Ac over-expressing cells (Fig. 1d).
We have previously reported that PP2Ac negatively
modulates the IFNa-induced ISG expression by reducing
the methylation on STAT1 via the inhibition of PRMT1
activity [18]. Therefore, to distinguish the effect of
PP2Ac over-expression on STAT1 phosphorylation from
its inhibitory effect on PRMT1, we performed experiments
knocking down PRMT1. UPP2A-C8 were silenced for
PRMT1 using a lentiviral expression system (Fig. 1e) and
cultured in the presence or absence of tetracycline to
induce PP2Ac over-expression. The functional effect of
shPRMT1 knockdown was evaluated by analysis of meth-
ylation on histone H4 at arginine 3, a known substrate
for PRMT1 [26]. Figure 1e shows that PRMT1 silencing
leads to a decrease in methylation on H4. The cells were
then stimulated with 100 IU/mL of IFNa, and the ISG
expression was quantified by RT-qPCR. Figure 1f shows a
significant diminution of STAT1 and IP10 expression
upon IFNa stimulation in PP2Ac over-expressing cells in
the absence of PRMT1 demonstrating that the reduction
in ISG expression in PP2Ac over-expressing cells was
caused by the inhibitory effect of PP2Ac on STAT1
phosphorylation.
We further validated these results on a cell line with a
stable silencing of PP2Ac. The decrease in PP2Ac expres-
sion level was verified by immunoblotting (Fig. 2a). We
then analysed STAT1 tyrosine and serine phosphoryla-
tion upon IFNa stimulation. The reduction in PP2Ac
expression enhanced STAT1 phosphorylation on serine
and tyrosine residues in response to IFNa stimulation
(Fig. 2b; lanes 2, 3, 4 vs 6, 7, 8, respectively). The
increased STAT1 activation in PP2Ac-silenced cells
resulted in a stronger STAT1-probe binding shown by
EMSA (Fig. 2c; lanes 2, 3, 4 vs 6, 7, 8 respectively).
Consequently, we observed a significant enhanced expres-
sion of the ISGs in PP2Ac-silenced cells upon IFNa stim-
ulation (Fig. 2d).
© 2013 John Wiley & Sons Ltd






PP2Ac does not modulate the dephosphorylation rate of
STAT1 on tyrosine residues
Next, we analysed whether the enhanced STAT1 tyrosine
phosphorylation observed in PP2Ac silenced cells is caused
by a slower dephosphorylation due to the absence of
PP2Ac. We exposed PP2Ac silenced and control cells for
different durations to IFNa and quantified the pY-STAT1
signal. It is well known that the IFNa signalling becomes
refractory after an initial activation inhibiting re-activation
of STAT1 by IFNa [27]. Indeed, cells exposed to IFNa rap-
idly showed strong STAT1 phosphorylation followed by a
gradual decrease in pY-STAT1 until complete disappear-
ance of the signal at 8-h postexposure due to a refractory
period (Fig. S1). Interestingly, the time-course analysis of
pY-STAT1 after IFNa stimulation revealed a comparable
decrease rate of the pY-STAT1 signal intensity between
control and PP2Ac-silenced cells (Fig. S1; lanes 1, 2, 3 vs
7, 8, 9, respectively) suggesting that the dephosphorylation
process of tyrosine residues was not affected by PP2Ac
silencing. Therefore, the enhanced pY-STAT1 signal
observed in PP2Ac-silenced cells upon IFNa stimulation









































































































































































Fig. 1 PP2Ac over-expression impairs IFNa-mediated STAT1 activation and ISGs expression. (a) C57BL/6 mice (n = 2)
were injected subcutaneously with 1000 IU of IFNa per g of body weight for 1 h and 500 lg of total protein from
mouse liver homogenate were used to immunoprecipitate STAT1. The PP2Ac signal was detected by immunoblotting.
The experiment was performed in duplicate. A representative blot is shown. (b) UPP2A-C8 cells were cultured in the
presence or absence of tetracycline for 24 h and the expression level of PP2Ac analysed by immunoblotting.
(c) PP2Ac over-expression was achieved by removing tetracycline from the culture medium for 24 h prior to
stimulation with increasing concentrations of IFNa for 15 min. pY-STAT1 and STAT1 signals were visualized by
immunoblotting and then quantified using ImageJ. Shown is a representative result from 2 independent experiments.
(d) Total RNA from cells unstimulated or stimulated with 100U/mL IFNa for 4 h were extracted and cDNA prepared.
STAT1 and IP10 expression levels were measured by qPCR. Results (n = 3) are expressed as means ! SEM. The
statistical significance was assessed using Fisher’s exact t-test. Shown are the representative results from 3 independent
experiments. (e) PRMT1 was silenced in UPP2A-C8 cells using a lentiviral system. PRMT1 expression was then
analysed by quantitative RT-PCR and by immunoblotting. (f) UPP2A-C8 cells were silenced for PRMT1 and then
cultured in the presence or absence of tetracycline for 24 h. Cells were stimulated with 100 IU/mL IFNa for 4 h and
the expression of STAT1 and IP10 was measured by qPCR. Results (n = 3) are expressed as means ! SEM. The
statistical significance was assessed using Fisher’s exact t-test.
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PP2Ac associates with Jak1/Tyk2/STAT1 in response to
IFNa stimulation and modulates Jak1/Tyk2
phosphorylation
We further investigated the mechanism by which PP2Ac
controls IFNa-mediated STAT1 phosphorylation by per-
forming a coimmunoprecipitation assay. Our results show
that PP2Ac associates with STAT1 upon IFNa stimulation
in Huh7 cells (Fig. 3a). This binding was also observed
with Jak1 and Tyk2 (Fig. 3b) suggesting that PP2Ac might
have a direct regulatory role on Jak1/Tyk2 and STAT1
activation.
As we have observed that PP2Ac associates with Jak1
and Tyk2, we analysed the effect of PP2Ac on Jak1 and
Tyk2 activation. Time-course analysis of IFNa-treated cells
revealed a stronger phosphorylation of Jak1 and Tyk2 in
cells silenced for PP2Ac compared with control cells
(Fig. 3c; lane 2 vs 6).
PP2A catalytic activity is not required to inhibit Jak and
STAT1 tyrosine phosphorylation
Next, we investigated if the catalytic activity of PP2Ac is
required to inhibit Jak and STAT1 phosphorylation. We
treated Huh7 cells with okadaic acid (OA) to block PP2A
activity. The inhibition of the phosphatase activity was
confirmed by a strong pS-Akt signal (Fig. 4a, asterisk), a
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Fig. 2 PP2Ac silencing enhances pY-STAT1 signals, DNA binding and ISGs expression. (a) PP2Ac silencing was obtained
by stable transfection of Huh7 with scrambled or shPP2Ac plasmids. The expression of PP2Ac was analysed by
immunoblotting. (b) A kinetic of stimulation with 100U/mL IFNa was performed. pY-STAT1 and pS-STAT1 signals were
visualized by immunoblotting and then quantified using ImageJ. Results are representative of 3 independent experiments.
(c) Nuclear extracts from scramble and shPP2Ac were prepared, and STAT1-DNA binding was visualized by EMSA using
GAS probe. Cells were treated with 100U/mL IFNa for the indicated time. STAT1 homodimer bands were quantified using
ImageJ. Shown is a representative result from 2 independent experiments. (d) STAT1, IP10, GBP1 and SOCS1 expression
levels were analysed by qPCR upon stimulation with 100U/mL IFNa for 4 h. Results (n = 3) are expressed as
means ! SEM. Shown are representative results from 4 independent experiments.
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inhibition of PP2A activity by OA does not alter Jak1/
Tyk2/STAT1 phosphorylation (Fig. 4a; lane 2 vs 3).
Because OA can affect multiple phosphorylation events
simultaneously, we confirmed our observations by trans-
fecting Huh7 cells with two PP2Ac mutant plasmids
(D88N and H118N) that abolish PP2A catalytic activity
[29] (Fig. 4b) and analysed pY-STAT1 upon IFNa stimula-
tion. The expression level of mutant PP2Ac was analysed
by immunoblotting (Fig. 4b,c). We found that both con-
structs significantly reduced tyrosine phosphorylation of
STAT1 demonstrating that the phosphatase activity is not
required for the inhibition of IFNa-induced pY-STAT1 sig-
nal (Fig. 4c).
PP2Ac modulates IFNa-mediated antiviral activity
against HCV
Our finding that PP2A negatively modulates the pY-STAT1
strength suggests an effect of PP2A on IFNa-mediated an-
tiviral activity. We therefore performed a functional assay
using an HCV fully infectious system. We silenced PP2Ac
in Huh7.5.1 cells prior infection with HCVcc and studied
the antiviral effect of IFNa. Silencing of PP2Ac for 4 days
did not significantly affect cell proliferation (Fig. S2). How-
ever, we observed a significant impairment of HCVcc repli-
cation (Fig. 5a–c). To investigate if the catalytic activity of
PP2A is involved in the modulation of HCV replication, we
treated cells with OA and infected them with HCVcc. We
found that the core protein signal is weaker in OA-treated
cells (Fig. S3; lane 3 vs 4) suggesting that HCV replication
is dependent on the phosphatase activity. We confirmed
our results by infecting Huh7.5.1 cells transfected with
wild type (WT) or mutant (H118N) PP2Ac. Ectopic expres-
sion of WT-PP2Ac significantly increased core expression
after 3 days of infection (Fig. 5d; lane 3 vs 2). As expected,
HCV replication in H118N–PP2Ac-transfected cells was
similar to mock-transfected cells (Fig. 5d; lane 4 vs 5) dem-
onstrating that the phosphatase activity supports HCVcc
replication.
Next, we wanted to study the effect of PP2Ac on IFNa-
mediated antiviral activity. Because PP2Ac catalytic activ-
ity positively modulates HCVcc replication, we performed
the experiment using a PP2Ac mutant (H118N) that
allows increased expression of PP2Ac without up-regulat-
ing the phosphatase activity. Huh7.5.1 cells transfected
with H118N-PP2Ac or mock plasmid were infected with
HCVcc and then treated with IFNa. Our results showed
that the expression of the mutant impairs the IFNa-induced
antiviral response (Fig. 5e,f; lane 4 vs 2). Because the inhi-
bition of pY-STAT1 by PP2Ac is independent of the cata-
lytic activity and the effect of PP2Ac on HCV replication
requires the phosphatase activity to reduce NS3 methyla-
tion [30], we can conclude that the effect observed with
the H118N mutant results mainly from the inhibition of
STAT1 phosphorylation by PP2Ac.
DISCUSSION
The rapid production of IFN is a crucial step to limit viral
propagation. Therefore, to establish a persistent infection
pY-Tyk2
pY-Jak1
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Fig. 3 PP2Ac associates with Jak1/Tyk2/STAT1 upon IFNa stimulation and impairs Jak1/Tyk2 activation. (a) Huh7 cells
were stimulated with 100 IU/mL IFNa and STAT1 was immunoprecipitated. The PP2Ac signal was then detected by
immunoblotting. Results are representative of 2 independent experiments. (b) Huh7 cells were stimulated with 100 IU/mL
IFNa and PP2Ac was immunoprecipitated. Jak1 and Tyk2 signals were detected by immunoblotting. Results are
representative of 2 independent experiments. (c) Scrambled and PP2Ac-silenced cells were treated with 100U/mL IFNa for
the indicated time and then analysed for pY-Jak1 and pY-Tyk2 signals. Protein bands were quantified using ImageJ.
Results are representative of 2 independent experiments.
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viruses have to develop a strategy to counteract this first
line of defence of the host cell. We have reported that HCV
infection leads to an activation of the ER stress response in
the host cell resulting in an up-regulation of PP2Ac [20].
Several viruses are known to alter the expression of PP2A.
Indeed, we have previously demonstrated that HBV also
induces an up-regulation of the PP2A catalytic subunit
[19]. Furthermore, it has been reported that PP1 and
PP2A expression are increased during cytomegalovirus
infection demonstrating that the deregulation of PP2Ac
expression is not restricted to hepatotropic viruses [31].
PP2Ac associates with PRMT1 and inhibits the methyl-
transferase activity in a PP2A catalytic activity dependent
manner, resulting in a reduction in methylation levels of
STAT1 and of the NS3 helicase. Hypomethylated STAT1
associates to Pias1 preventing the binding of activated
STAT1 to the promoter of target genes [18]. Hypomethy-
lated NS3 has increased helicase activity favouring HCV
replication [30]. In the present study, we report an
interesting observation that PP2Ac associates with
Jak1/Tyk2/STAT1 upon IFNa stimulation and impairs
phosphorylation of tyrosine residues independently of the
catalytic activity. Together with our previously published
results, these data suggest that the over-expression of
PP2Ac in the context of viral infection modulates the
IFNa-induced Jak-STAT signalling pathway at two distinct
levels. We believe that this particularity confers an impor-
tant role to PP2Ac in the establishment of chronic infec-
tion. Indeed, STAT1 is continuously methylated by PRMT1
in the cell [32]. Presently, only two enzymes are described,
based on histone work, to remove methyl groups from
arginine residues. The peptidylarginine deiminase 4 is
known to convert the methyl group to citrulline [33] and
the Jumonji domain-containing proteins are identified to
regenerate arginine residues from methylated histones
[34]. It is unknown whether methylated arginine residues
on STAT1 could be removed via these mechanisms. There-
fore, we hypothesize that the only way to reverse the
methylation effect on STAT1 would be to degrade the pro-
tein. Thus, the negative regulation of PP2Ac on STAT1
transcriptional activity via PRMT1 is effective only on
newly transcribed STAT1. STAT1 protein is stable and has
a half life of over 24 h [35]; therefore, the inhibitory effect
of PP2Ac on STAT1 phosphorylation would allow the
virus to immediately block the early host antiviral response
induced by IFNa.
Previously, it was reported that okadaic acid, a specific
inhibitor of PP2A, induces pS727-STAT3 in human anti-
gen-specific CD4+ T-cell lines and cutaneous T-cell lym-
phoma lines [36]. Furthermore, PP2Ac has been shown to
physically associate with a macromolecular protein com-
plex composed by mTOR, STAT1 and Tap42 suggesting a
potential regulatory effect of PP2Ac on STAT1 phosphory-
lation [37]. We show in this study that PP2Ac associates
with Jak1/Tyk2/STAT1 and impairs their activation. How-
ever, the mechanism used by PP2A to reduce Jak1/Tyk2/
STAT1 phosphorylation remains unclear. It might be
through a physical interaction of PP2Ac to Jak1/Tyk2/
STAT1 disrupting the phosphorylation events. Addition-
ally, PP2A could also be a tyrosine phosphatase under par-
ticular conditions [25]. Indeed, the catalytic subunit can
be phosphorylated on tyrosine 307 leading to the inactiva-
tion of the enzyme [22]. This phosphatase can be re-acti-
vated through autodephosphorylation suggesting a
tyrosine phosphatase activity [25]. However, our findings
that PP2Ac silencing did not affect the STAT1 dephosphor-
ylation rate suggest that the inhibitory effect of PP2Ac on
STAT1 phosphorylation is not caused by a tyrosine phos-
phatase activity of PP2A. The PP2A catalytic subunit is
phosphorylated on tyrosine residues by epidermal growth
factor (EGF), insulin or p60v-src leading to the inactivation
of the phosphatase [22,38]. Furthermore, we have
observed that IFNa induces PP2Ac phosphorylation (data
not shown) suggesting an inhibition of PP2Ac activity by
IFNa. Therefore, a blockade of STAT1 activation in a








































































Fig. 4 The phosphatase activity of PP2A is not required to
inhibit the IFNa-mediated STAT1 tyrosine phosphorylation.
(a) Huh7 cells were exposed to 100 nM Okadaic acid for
3 h prior to been treated with 100U/mL IFNa for 30 min.
Indicated proteins were detected by Western blotting.
Asterisk shows pS-Akt specific band. Shown is a
representative result from 3 independent experiments.
(b) Huh7 cells were transiently transfected for 24 h with
plasmid for HA-PP2Ac WT, H118N or D88N. Cells were
then stimulated with PBS or 100 nM insulin for 5 min and
pS-Akt signal was monitored. (c) Huh7 cells were
transiently transfected for 24 h with plasmid for HA-
PP2Ac D88N, or H118N. Cells were stimulated with
100U/mL IFNa for 1 h and the pY-STAT1 signal was
visualized. Shown is a representative result from 3
independent experiments.
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beneficial for a virus to immediately and efficiently coun-
teract the IFNa antiviral response.
Heretofore, it is unclear whether PP2Ac exists as a free
subunit in the cell. Considering that the C subunit forms a
dimer with the A subunit [39], we have silenced PP2Aa
and investigated the effect of PP2Aa knockdown on IFNa-
induced pY-STAT1 signals. We did not observe any alter-
ation of the pY-STAT1 signal in PP2Aa silenced cells (data
not shown) suggesting that the A subunit does not partici-
pate in the inhibitory effect of the C subunit on STAT1
phosphorylation.
During viral infection, the protein kinase R (PKR) and
the eukaryotic translation initiation factor 2 (eIF2) are
phosphorylated on threonine and serine residues, respec-
tively, leading to an inhibition of de novo protein synthesis
[40]. This reduction in translation initiation limits the syn-
thesis of antiviral proteins but also perturbs the virus life
cycle [41,42]. Therefore, it is important that the virus
develops a strategy to block the host antiviral response
without impairing its replication. Our data demonstrate
that PP2A could be that key player. Indeed, by inhibiting
the Jak-STAT signalling pathway through PP2Ac up-regu-
lation, HCV could counteract the early immune response.
Additionally, PP2Ac over-expression blocks PRMT1 activity
leading to hypomethylation of STAT1 and NS3 helicase.
The reduction in methylation of the NS3 helicase enhances
the unwinding activity of the helicase favouring viral repli-
cation [30], whereas the hypomethylation of STAT1 inhib-
its the late IFNa-induced antiviral response [18]. Our data
provide evidence that the protein expression level and the
catalytic activity of PP2A inhibits the interferon a signal-
ling pathway and favours viral replication, suggesting that
PP2A could be a key player in the establishment of a
chronic infection (Fig. S4).
PP2A is highly expressed in the cell and is frequently
targeted by viral proteins to subvert selectively important
cellular pathways leading to enhanced viral replication
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Fig. 5 PP2A negatively modulates the IFNa-mediated HCV antiviral activity. (a) PP2Ac was silenced in Huh7.5.1 cells
using short-hairpin technology and then infected with JC1 HCVcc particles. HCV core and NS3 proteins were analysed by
immunoblotting. (b) Immunostaining of HCV core after 3 days of infection with 1MOI HCVcc. (c) Analysis of HCV and
PP2Ac expression in PP2Ac silenced cells by qPCR (n = 3). Shown is a representative result from 2 independent
experiments. (d) Huh7.5.1 cells were transfected with wild type (WT) or the mutant H118N PP2A plasmid for 10 h prior
to being infected with HCVcc. HCV core was visualized by immunoblotting. Shown is a representative result from 3
independent experiments. (e) Huh7.5.1 cells were transfected with H118N-PP2Ac or mock plasmids and then treated with
100U/mL IFNa for 24 h. HCV core was visualized by immunoblotting. Shown is a representative result from 2 independent
experiments. (f) Analysis of HCV expression 24 h after IFNa treatment by qPCR in Huh7.5.1 cells transfected with H118N-
PP2Ac or mock plasmids (n = 2). A representative result from 2 independent experiments is shown in this figure.
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the MCV small T-Antigen is required for the accomplish-
ment of the virus life cycle [43]. Furthermore, it has
been reported that the small t antigens and the polyoma-
virus middle T proteins can associate with the PP2A core
and induce cell transformation [44]. These observations
identify PP2A as a potential key target for therapeutic
developments. Presently, two natural antitumour mole-
cules, cantharidin and fostriecin that specifically bind and
inhibit PP2A have been tested for hepatoma and oesoph-
ageal carcinomas [45,46]. Although these compounds
are potent antitumour molecules, their use has severe
side effects probably due to the inhibition of PP2A that
is the major phosphatase in the cell. Therefore, a precise
mechanistic analysis of PP2A will permit the develop-
ment of better drugs improving the benefit to side effects
ratio.
ACKNOWLEDGEMENTS
We are grateful to Dr. Sinicrope for the pSIH1-puro-control
shRNA plasmid [47]. This study was funded by grants
from the Swiss National Science Foundation (grant
3L0030_130243) and the Swiss Cancer League grant
(KLS-02522-02-2010).
REFERENCES
1 Kanneganti TD. Central roles of
NLRs and inflammasomes in viral
infection. Nat Rev Immunol 2010;
10: 688–698.
2 Wang Y, Swiecki M, McCartney SA,
Colonna M. dsRNA sensors and
plasmacytoid dendritic cells in host
defense and autoimmunity. Immunol
Rev 2011; 243: 74–90.
3 Silvennoinen O, Ihle JN, Schlessinger J,
Levy DE. Interferon-induced nuclear
signalling by Jak protein tyrosine
kinases. Nature 1993; 366: 583–
585.
4 Darnell JE Jr, Kerr IM, Stark GR. Jak-
STAT pathways and transcriptional
activation in response to IFNs and
other extracellular signaling proteins.
Science 1994; 264: 1415–1421.
5 Shuai K, Horvath CM, Huang LH
et al. Interferon activation of the
transcription factor Stat91 involves
dimerization through SH2-phospho-
tyrosyl peptide interactions. Cell
1994; 76: 821–828.
6 Arnheiter H, Skuntz S, Noteborn M,
Chang S, Meier E. Transgenic mice
with intracellular immunity to influ-
enza virus. Cell 1990; 62: 51–61.
7 Carroll K, Elroy-Stein O, Moss B, Ja-
gus R. Recombinant vaccinia virus
K3L gene product prevents activa-
tion of double-stranded RNA-depen-
dent, initiation factor 2 alpha-
specific protein kinase. J Biol Chem
1993; 268: 12837–12842.
8 Marie I, Rebouillat D, Hovanessian
AG. The expression of both domains
of the 69/71 kDa 2′,5′ oligoadeny-
late synthetase generates a catalyti-
cally active enzyme and mediates an
anti-viral response. Eur J Biochem
1999; 262: 155–165.
9 Starr R, Willson TA, Viney EM et al.
A family of cytokine-inducible inhib-
itors of signalling. Nature 1997;
387: 917–921.
10 Liu B, Liao J, Rao X et al. Inhibition
of Stat1-mediated gene activation
by PIAS1. Proc Natl Acad Sci USA
1998; 95: 10626–10631.
11 Ten Hoeve J, De Jesus Ibarra-San-
chez M, Fu Y et al. Identification of
a nuclear Stat1 protein tyrosine
phosphatase. Mol Cell Biol 2002;
22: 5662–5668.
12 Malakhov MP, Malakhova OA, Kim
KI, Ritchie KJ, Zhang DE. UBP43
(USP18) specifically removes ISG15
from conjugated proteins. J Biol
Chem 2002; 277: 9976–9981.
13 Hendrix P, Turowski P, Mayer-Jae-
kel RE et al. Analysis of subunit iso-
forms in protein phosphatase 2A
holoenzymes from rabbit and Xeno-
pus. J Biol Chem 1993; 268: 7330–
7337.
14 Zhou J, Pham HT, Walter G. The
formation and activity of PP2A
holoenzymes do not depend on
the isoform of the catalytic sub-
unit. J Biol Chem 2003; 278:
8617–8622.
15 Baharians Z, Schonthal AH. Autore-
gulation of protein phosphatase
type 2A expression. J Biol Chem
1998; 273: 19019–19024.
16 Voorhoeve PM, Hijmans EM, Ber-
nards R. Functional interaction
between a novel protein phospha-
tase 2A regulatory subunit, PR59,
and the retinoblastoma-related
p107 protein. Oncogene 1999; 18:
515–524.
17 Duong FH, Christen V, Lin S, Heim
MH. Hepatitis C virus-induced
up-regulation of protein phospha-
tase 2A inhibits histone modifica-
tion and DNA damage repair.
Hepatology 2010; 51: 741–751.
18 Duong FH, Filipowicz M, Tripodi M,
La Monica N, Heim MH. Hepatitis C
virus inhibits interferon signaling
through up-regulation of protein
phosphatase 2A. Gastroenterology
2004; 126: 263–277.
19 Christen V, Duong F, Bernsmeier C,
Sun D, Nassal M, Heim MH. Inhibi-
tion of alpha interferon signaling by
hepatitis B virus. J Virol 2007; 81:
159–165.
20 Christen V, Treves S, Duong FH,
Heim MH. Activation of endoplas-
mic reticulum stress response by
hepatitis viruses up-regulates pro-
tein phosphatase 2A. Hepatology
2007; 46: 558–565.
21 Kamibayashi C, Estes R, Lickteig
RL, Yang SI, Craft C, Mumby MC.
Comparison of heterotrimeric pro-
tein phosphatase 2A containing dif-
ferent B subunits. J Biol Chem
1994; 269: 20139–20148.
22 Chen J, Parsons S, Brautigan DL.
Tyrosine phosphorylation of protein
phosphatase 2A in response to
growth stimulation and v-src trans-
formation of fibroblasts. J Biol Chem
1994; 269: 7957–7962.
23 Bryant JC, Westphal RS, Wadzinski
BE. Methylated C-terminal leucine
residue of PP2A catalytic subunit is
important for binding of regulatory
Balpha subunit. Biochem J 1999;
339(Pt 2): 241–246.
24 Pietschmann T, Kaul A, Koutsouda-
kis G et al. Construction and char-
acterization of infectious intrageno-
typic and intergenotypic hepatitis C
© 2013 John Wiley & Sons Ltd






virus chimeras. Proc Natl Acad Sci
USA 2006; 103: 7408–7413.
25 Guo H, Damuni Z. Autophosphory-
lation-activated protein kinase phos-
phorylates and inactivates protein
phosphatase 2A. Proc Natl Acad Sci
USA 1993; 90: 2500–2504.
26 Huang S, Litt M, Felsenfeld G. Meth-
ylation of histone H4 by arginine
methyltransferase PRMT1 is essen-
tial in vivo for many subsequent his-
tone modifications. Genes Dev 2005;
19: 1885–1893.
27 Makowska Z, Duong FH, Trincucci
G, Tough DF, Heim MH. Interferon-
beta and interferon-lambda signaling
is not affected by interferon-induced
refractoriness to interferon-alpha
in vivo. Hepatology 2011; 53: 1154–
1163.
28 Ugi S, Imamura T, Maegawa H
et al. Protein phosphatase 2A nega-
tively regulates insulin’s metabolic
signaling pathway by inhibiting Akt
(protein kinase B) activity in 3T3-
L1 adipocytes. Mol Cell Biol 2004;
24: 8778–8789.
29 Myles T, Schmidt K, Evans DR,
Cron P, Hemmings BA. Active-site
mutations impairing the catalytic
function of the catalytic subunit of
human protein phosphatase 2A per-
mit baculovirus-mediated overex-
pression in insect cells. Biochem J
2001; 357: 225–232.
30 Duong FH, Christen V, Berke JM,
Penna SH, Moradpour D, Heim MH.
Upregulation of protein phosphatase
2Ac by hepatitis C virus modulates
NS3 helicase activity through inhi-
bition of protein arginine methyl-
transferase 1. J Virol 2005; 79:
15342–15350.
31 Hakki M, Geballe AP. Cellular ser-
ine/threonine phosphatase activity
during human cytomegalovirus
infection. Virology 2008; 380: 255–
263.
32 Mowen KA, Tang J, Zhu W et al.
Arginine methylation of STAT1 mod-
ulates IFNalpha/beta-induced tran-
scription. Cell 2001; 104: 731–741.
33 Wang Y, Wysocka J, Sayegh J et al.
Human PAD4 regulates histone
arginine methylation levels via
demethylimination. Science 2004;
306: 279–283.
34 Chang B, Chen Y, Zhao Y, Bruick
RK. JMJD6 is a histone arginine de-
methylase. Science 2007; 318: 444–
447.
35 Blesofsky WA, Mowen K, Arduini
RM et al. Regulation of STAT pro-
tein synthesis by c-Cbl. Oncogene
2001; 20: 7326–7333.
36 Woetmann A, Nielsen M, Christen-
sen ST et al. Inhibition of protein
phosphatase 2A induces serine/
threonine phosphorylation, subcel-
lular redistribution, and functional
inhibition of STAT3. Proc Natl Acad
Sci USA 1999; 96: 10620–10625.
37 Fielhaber JA, Han YS, Tan J et al.
Inactivation of mammalian target of
rapamycin increases STAT1 nuclear
content and transcriptional activity
in alpha4- and protein phosphatase
2A-dependent fashion. J Biol Chem
2009; 284: 24341–24353.
38 Chen J, Martin BL, Brautigan DL.
Regulation of protein serine-threo-
nine phosphatase type-2A by tyro-
sine phosphorylation. Science 1992;
257: 1261–1264.
39 Ruediger R, Brewis N, Ohst K, Wal-
ter G. Increasing the ratio of PP2A
core enzyme to holoenzyme inhibits
Tat-stimulated HIV-1 transcription
and virus production. Virology
1997; 238: 432–443.
40 Taylor SS, Haste NM, Ghosh G.
PKR and eIF2alpha: integration of
kinase dimerization, activation, and
substrate docking. Cell 2005; 122:
823–825.
41 Kang JI, Kwon SN, Park SH et al.
PKR protein kinase is activated by
hepatitis C virus and inhibits viral
replication through translational
control. Virus Res 2009; 142: 51–
56.
42 Wang C, Pflugheber J, Sumpter R Jr
et al. Alpha interferon induces dis-
tinct translational control programs
to suppress hepatitis C virus RNA
replication. J Virol 2003; 77: 3898–
3912.
43 Kwun HJ, Guastafierro A, Shuda M
et al. The minimum replication ori-
gin of merkel cell polyomavirus has
a unique large T-antigen loading
architecture and requires small
T-antigen expression for optimal
replication. J Virol 2009; 83:
12118–12128.
44 Pallas DC, Shahrik LK, Martin BL
et al. Polyoma small and middle T
antigens and SV40 small t antigen
form stable complexes with protein
phosphatase 2A. Cell 1990; 60:
167–176.
45 Walsh AH, Cheng A, Honkanen RE.
Fostriecin, an antitumor antibiotic
with inhibitory activity against ser-
ine/threonine protein phosphatases
types 1 (PP1) and 2A (PP2A), is
highly selective for PP2A. FEBS Lett
1997; 416: 230–234.
46 Swingle M, Ni L, Honkanen RE.
Small-molecule inhibitors of ser/thr
protein phosphatases: specificity, use
and common forms of abuse. Meth-
ods Mol Biol 2007; 365: 23–38.
47 Huang S, Sinicrope FA. Sorafenib
inhibits STAT3 activation to
enhance TRAIL-mediated apoptosis
in human pancreatic cancer cells.
Mol Cancer Ther 2010; 9: 742–750.
SUPPORTING INFORMATION
Additional Supporting Information
may be found in the online version of
this article:
Fig. S1. PP2Ac does not alter the
rate of pY-STAT1 dephosphorylation.
Fig. S2. PP2Ac silencing does not
modulate cell proliferation.
Fig. S3. Inhibition of PP2A cata-
lytic activity alters HCVcc replication.
Fig. S4. PP2Ac up-regulation
favours the establishment of a
chronic infection.
© 2013 John Wiley & Sons Ltd







1.5 4 8 4824 .5 48 h
scramble shPP2Ac

























































































1 2 3 4
Figure S3
PP2Ac














4.2 The role of PP2A-A and -B subunits in the regulation of the Jak-
STAT signaling pathway. 
Because PP2A is a multimeric holoenzyme and the substrates recognition is determined 
through the association to specific regulatory B subunits, we have tried to identify which B 
subunit could potentially be an important component in PP2Ac-mediated inhibition of the 
IFN-α induced Jak-STAT signaling. For that purpose, we have serially silenced several B 






Figure 1: Silencing of various PP2A-B isoforms. Silencing of PP2A-B55 or B isoforms 
(A), B56 or B` isoforms (B) and B72 or B`` isoforms. Huh7 cells were stably transfected 
with sh-scramble and sh-RNA against particular isoforms as indicated. The mRNA 
expression of silenced isoforms (grey color bar) against sh-scramble (black color bar) is 






4.2.1  Effect of silencing of a specific PP2A subunit on the expression of the 
other subunits 
The phosphatase activity is mainly provided by the α isoform of the catalytic C subunit in 
specific association with B subunits.  Therefore, it is likely that alteration of a particular B 
subunit could modify the proportion of holoenzyme complexes and localization into 
subcellular compartments. This could affect the various cellular processes including genes 
transcription, RNA/protein stability. Therefore, in order to identify which specific PP2A-B 
subunits regulate INF-α signaling and HCV replication we serially silenced various 
isoforms of PP2A subunits. Interestingly, qRT-PCR results show that silencing of a 
particular isoform of B subunit leads to a down-regulation of majority of the other 
isoforms. Additionally, this impairment is not only restricted to A, B or C subunits but also 
deregulates the expression of other regulatory proteins such as α4. As shown in figure 2, 
we observed a down-regulation of PP2A-Aα in cells silenced for PP2A-cα, B55α, and 
B56β. We also observed that PP2A-Aα expression was up-regulated in PP2A-B56α 
silenced cells (figure 2A). Furthermore, PP2A-B55α expression was unchanged in PP2A-
Aα silenced cells though we observed significant down-regulation of PP2A-B55α in 
PP2A-B56α/β cells (figure 2B). Interestingly, we found that silencing of PP2A-B55α 
resulted in a decrease in PP2A-Aα expression (figure 2A) whereas silencing of PP2A-Aα 
did not impair PP2A-B55α expression (figure 2B). Our observation revealed that, silencing 
of PP2A-B55α and B56β down-regulates the expression of PP2A-B56α (figure 2C). 





2A) and vice-versa (figure 2C). Finally, silencing of PP2A-Aα, B55α, B56α, and B56β 
resulted in a decreased α4 expression (figure 2d). 
Additionally, silencing of the α isoform of the catalytic subunit attenuated the mRNA 
expression of various isoforms of PP2A including B56α-ε and B72α-γ (figure 3). This 
reduction is ranging from slight to moderate. These observations are summarized in table 2. 
Earlier, Sablina and colleagues have reported that silencing of PP2Acα leads to a 
significant reduction of the basal level of B55α, B56β, B56γ, PR93, and PP2A-A subunits 
whereas silencing of PP2A-Cβ exerts marginal effect on the expression of the other 
subunits (Sablina et al., 2010). Furthermore, it has been reported that an association of the 
PP2A-A with Cα subunit is required for their stability (Silverstein et al., 2002; Chen et al., 
2005b). Our observations are in the line with previous observations and show inter-
regulatory mechanisms governing the expression of various PP2A subunits. Such 
regulatory mechanism could be obtained through miRNAs that mediate mRNA degradation 
or/and activation/inhibition of various transcription factors. Because of the lack of 
commercially available antibodies against all the B subunits, we were not able to analyze 







Figure 2: Inter-regulation of different isoforms of PP2A. The X-axis represents the 
stably silenced cells while the Y-axis represents mRNA expression from indicated PP2A 

















4.2.2 Predication of miRNA targeting PP2A subunits 
One potential mechanism to explain the inter-regulation of the subunits expression could be 
through miRNAs. We, therefore, performed a miRNA targeting PP2A subunits analysis 
using online bioinformatics softwares such as miRBase 
(http://www.mirbase.org/index.shtml) or miRWalk (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/). Using this approach potential miRNAs was predicted 
against each subunit. We found that many subunits have multiple miRNA target sites. 
Interestingly, our miRNA and target genes data analysis revealed that miRNA-19 targets 4 
PP2A isoforms including B56α, B56ε, Aβ, and STRN3. Furthermore, we found that 
miRNA-34b targets Aβ and STRN isoforms. The role of various miRNA including 
miRNA-19, miRNA-1, and miRNA-34b involved in expression of PP2A subunits have 
















5. Discussion  
 
 
PP2A is known to regulate several signaling pathways via dephosphorylation of 
serine/threonine residues (Eichhorn et al., 2009). It has been shown that inhibition of PP2A 
increases serine phosphorylation on STAT6 and STAT3 (Woetmann et al., 1999, 2003) and 
also increases IFN-γ mediated serine and tyrosine phosphorylation of STAT1 in mTOR 
dependent fashion (Fielhaber et al., 2009). Recently, it has been reported that PP2A inhibits 
the Jak-STAT1 signaling by forming a macromolecular complex with mTOR, STAT1 and 
α4 and (Fielhaber et al., 2009). Moreover, it has been also shown that PP2A associates to 
Jak2 in myeloid progenitor cells and modulates the Jak2-STAT5 signaling pathway in 
response to IL-3 (Yokoyama et al., 2003). Presently, it is not clear how PP2Ac associates to 
Jak1 and Tyk2 and inhibits their activation. One could hypothesize that PP2Ac-Jak1/Tyk2 
binding shares similar molecular mechanism like PP2Ac-Jak2 association (Yokoyama et 
al., 2003). 
 
Production of IFNs by cells in response to viral infection leads to initiation of antiviral 
activity. For the establishment of persistent infection, viruses develop strategies to 
counteract this first line of defense. We have reported that HCV proteins inhibit the IFN-α 
signaling (Heim et al., 1999; Blindenbacher et al., 2003). The inhibition is mediated 
through an up-regulation of PP2Ac that leads to a hypomethylation of STAT1 (Duong et 
al., 2004). Hypomethylated STAT1 associates with PIAS1 and prevents activated STAT1 





 In this work, we demonstrated that the phosphatase activity of PP2A is not required for the 
inhibition of IFN-α induced Jak-STAT signaling. However, it is required to promote 
HCVcc replication. Indeed, using different approaches to reduce PP2A catalytic activity 
(pharmacological inhibitors, catalytic dead or dominant negative mutants, siRNA against 
PP2Ac), we have observed a reduction of HCV replication. The mechanism underlying 
regulation of viral life cycle by PP2A remains unclear. Three hypothesis could be proposed: 
(1) PP2A reduces the methylation of NS3 helicase by inhibiting PRMT1 leading to an 
enhanced unwinding activity and therefore viral replication (Duong et al., 2005); (2) PP2A 
dephosphorylates NS5A and induces viral replication (Evans et al., 2004); (3) PP2A 
dephosphorylates eIF2α (Groskreutz et al., 2010) and releases the inhibitory effect of 
eIF2α on protein translation thus favoring HCV replication. Further experiments are 
needed to clarify this issue. 
  
We have made an interesting observation that tyrosine phosphorylation of Jak1/Tyk2 and 
STAT1 is independent of PP2A phosphatase activity while it is needed to positively 
modulate HCV replication. This phenomenon can be explained by the complexity of 
substrate selection by PP2A. Indeed, depending on the B subunit that associates to the A-C 
core complex, PP2A holoenzyme could preferentially target the IFN-α signaling pathway 
or the HCV replication process. We have made an attempt to identify these B subunits 
using short-hairpin siRNA technology.  Unfortunately, we found that silencing of a specific 





identify the B subunits that are required to direct PP2A towards IFN-α signaling inhibition 
or towards HCV replication. 
 
The mechanism of subunits inter-regulation is not known. One possibility is that down-
regulation of a specific subunit alters the expression of some so far undiscovered miRNAs 
that then mediate RNA degradation of the other subunits. We have performed a PP2A and 
miRNA target gene analysis and observed that several subunits can be targeted by the same 
miRNA. Indeed, we found that miRNA-19 targets PP2A-B56ε subunits therefore one can 
hypothesize that silencing of one specific subunit increases the proportion of miRNA-19 
which then down-regulates the expression of the other subunits. Further experimentations 
are needed to clarify the mechanism underlying the inter-regulation of the expression of 
PP2A subunits. Another possible mechanism of inter-regulation of PP2A subunits could be 
via the regulation of transcription through epigenetic changes. Indeed, we have previously 
reported that PP2Ac can modify the post-translational modification status on histones such 
as methylation/acetylation/phosphorylation (Duong et al., 2010). There are several reports 
showing that modifications on histone can alter gene transcription by modifying the 
chromatin structure. These chromatin structure rearrangements lead to open/close 
chromatin status throughout the nucleosome facilitating/inhibiting the accessibility of 
transcription factors to the promoters (Berger, 2010). Therefore, the alteration of the 
expression of a specific PP2A subunit can change the modification status on histones and 
thus induces a change in the chromatin structure leading to an impairment of the expression 






The first part of the work demonstrate the role of PP2A in IFN-α induced Jak-STAT1 
signaling and HCV replication. We show here that PP2Ac activity is not required for IFN-α 
induced tyrosine phosphorylation of Jak1/Tyk2 and STAT1. In response to IFN-α 
induction, PP2Ac associates with Jak1/Tyk2 and STAT1. This association modulates the 
Jak1/Tyk2 and STAT1 tyrosine phosphorylation. However, this study shows that PP2A 
activity is required for the HCV replication. 
 
The selective behavior of PP2A for Jak-STAT1 signaling pathway inhibition and 
promotion of HCV replication could be due to the targeted substrate selection by PP2A 
holoenzyme complex. In the second part of this work, attempts were made to determine the 
specific regulatory B subunits involved in IFN-α induced Jak-STAT1 signaling inhibition 
and HCV replication. We observed the inter-regulatory behavior of PP2A subunits. During 
the course of this study, due to unavailability of specific antibodies for various isoforms of 
B subunit, the aim to determine specific holoenzyme complex involved in regulation of 
Jak-STAT1 signaling and HCV replication was not achieved.  
 
Further studies are required to investigate the specific B subunits and thereby holoenzyme 
complex responsible for IFN-α induced Jak-STAT signaling inhibition and HCV 
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